Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,20.600000381469727,23.950000762939453,20.25,21.0,56591,0.0,0.0,,,,,,,,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-06-28,21.399999618530273,21.950000762939453,20.200000762939453,21.399999618530273,24414,0.0,0.0,,,,,,,100.0,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-06-29,21.399999618530273,21.399999618530273,20.549999237060547,20.950000762939453,13201,0.0,0.0,,,,,,,45.21743067728747,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-06-30,20.950000762939453,20.950000762939453,19.959999084472656,20.149999618530273,15950,0.0,0.0,,,,,,,22.069848587567634,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-01,21.950000762939453,21.950000762939453,20.0,20.649999618530273,7784,0.0,0.0,,,,,,,42.04037106938882,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-04,20.649999618530273,21.450000762939453,20.200000762939453,20.75,8313,0.0,0.0,,,,,,,45.07211898939011,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-05,20.75,20.75,20.0,20.450000762939453,6958,0.0,0.0,,,,,,,38.55633839243347,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-06,20.299999237060547,20.850000381469727,20.299999237060547,20.75,8306,0.0,0.0,,,,,,,46.83349663327684,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-07,20.950000762939453,20.950000762939453,20.299999237060547,20.700000762939453,4430,0.0,0.0,,,,,,,45.72785866368823,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-08,20.700000762939453,20.850000381469727,20.200000762939453,20.5,2856,0.0,0.0,20.73000011444092,,,-1.1095036814818775,,,41.50673662471314,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-11,20.5,21.399999618530273,20.049999237060547,21.299999237060547,23627,0.0,0.0,20.760000038146973,,,2.60115220578667,,,58.148536547866875,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-12,21.5,21.700000762939453,20.700000762939453,21.100000381469727,13928,0.0,0.0,20.73000011444092,,,1.784854148510389,,,54.0113765935699,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-13,21.0,21.049999237060547,20.549999237060547,20.899999618530273,17693,0.0,0.0,20.725,,,0.8443889917021568,,,50.167455842478724,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-14,21.100000381469727,21.100000381469727,20.350000381469727,20.649999618530273,3824,0.0,0.0,20.775,,,-0.6016865534042125,,,45.781426438729966,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-15,20.649999618530273,20.75,20.200000762939453,20.700000762939453,3917,0.0,0.0,20.780000114440917,,,-0.3849824401390086,,,46.78354707331489,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-18,20.700000762939453,20.850000381469727,20.100000381469727,20.549999237060547,14714,0.0,0.0,20.760000038146973,,,-1.011564550580661,,,44.147355160111644,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-19,20.5,20.950000762939453,20.399999618530273,20.899999618530273,5541,0.0,0.0,20.804999923706056,,,0.45661953940202055,,,51.074813057319574,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-20,20.950000762939453,20.950000762939453,20.25,20.950000762939453,4585,0.0,0.0,20.825,,,0.6002437596132237,,,51.990927184321215,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-21,20.899999618530273,20.899999618530273,20.399999618530273,20.75,3803,0.0,0.0,20.829999923706055,,,-0.3840610849691313,,,48.11038581670346,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-22,20.799999237060547,21.75,20.100000381469727,21.399999618530273,18691,0.0,0.0,20.919999885559083,,,2.29445380304486,,,58.85808279922821,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-25,21.350000381469727,22.950000762939453,21.0,21.549999237060547,17981,0.0,0.0,20.94499988555908,,,2.8885144655388304,,,60.87218853112431,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-26,21.5,22.149999618530273,20.549999237060547,21.5,14607,0.0,0.0,20.98499984741211,,,2.454134650143453,,,59.8209317290867,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-27,21.5,21.75,20.799999237060547,21.5,17331,0.0,0.0,21.044999885559083,,,2.1620342927781855,,,59.820931729086695,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-28,21.850000381469727,21.850000381469727,20.950000762939453,21.399999618530273,8430,0.0,0.0,21.119999885559082,,,1.3257563186003745,,,57.51687671994602,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-07-29,20.75,21.799999237060547,20.75,21.450000762939453,22081,0.0,0.0,21.19499988555908,,,1.2031180880265686,,,58.38006208751399,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-01,21.649999618530273,22.299999237060547,20.950000762939453,22.0,12218,0.0,0.0,21.339999961853028,,,3.0927836894413083,,,66.4541467761054,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-02,21.399999618530273,23.5,21.399999618530273,23.0,30356,0.0,0.0,21.55,,,6.728538283062642,,,75.68880421006553,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-03,23.0,23.5,22.350000381469727,23.5,27055,0.0,0.0,21.804999923706056,,,7.773446834325215,,,78.82724542402121,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-04,24.0,24.899999618530273,23.399999618530273,23.700000762939453,21955,0.0,0.0,22.1,,,7.2398224567396,,,79.9426381753929,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-05,23.700000762939453,24.850000381469727,23.600000381469727,24.200000762939453,40303,0.0,0.0,22.380000114440918,,,8.132263803359686,,,82.43404804372541,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-08,23.899999618530273,23.899999618530273,23.25,23.700000762939453,17037,0.0,0.0,22.59500026702881,,,4.890464628686413,,,72.70796360151093,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-09,23.5,23.700000762939453,22.850000381469727,23.549999237060547,12153,0.0,0.0,22.800000190734863,,,3.2894694739101684,,,70.0381767099633,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-10,23.549999237060547,23.549999237060547,23.0,23.549999237060547,14228,0.0,0.0,23.005000114440918,,,2.3690463808236055,,,70.03817670996328,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-11,23.549999237060547,23.950000762939453,22.450000762939453,23.399999618530273,40411,0.0,0.0,23.205000114440917,,,0.8403339932241769,,,67.17741459914252,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-12,23.399999618530273,23.75,22.649999618530273,23.5,8934,0.0,0.0,23.410000038146972,,,0.3844509257000071,,,68.11252571669854,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-15,22.850000381469727,23.149999618530273,22.399999618530273,22.5,16506,0.0,0.0,23.460000038146973,,,-4.092071767203628,,,52.12110428819064,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-16,22.5,23.350000381469727,22.25,22.350000381469727,14059,0.0,0.0,23.395000076293947,,,-4.466765084062187,,,50.216598852846474,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-17,21.799999237060547,23.0,21.799999237060547,22.600000381469727,6603,0.0,0.0,23.30500011444092,,,-3.025100748806003,,,53.28067599881076,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-18,23.0,23.0,21.600000381469727,22.0,18310,0.0,0.0,23.135000038146973,,,-4.90598675718819,,,45.968136408737784,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-19,22.299999237060547,22.649999618530273,20.899999618530273,21.850000381469727,15281,0.0,0.0,22.9,21.73250002861023,,-4.585151172621275,5.372138363523702,,44.33011099966703,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-22,21.850000381469727,22.450000762939453,21.149999618530273,21.899999618530273,20067,0.0,0.0,22.719999885559083,21.755000019073485,,-3.609156123059689,4.43576127621027,,45.03321885261829,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-23,22.100000381469727,23.450000762939453,21.549999237060547,21.799999237060547,8940,0.0,0.0,22.544999885559083,21.76500000953674,,-3.304505000134139,3.583734783737971,,43.84060167154097,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-24,21.5,21.799999237060547,20.950000762939453,21.649999618530273,25904,0.0,0.0,22.354999923706053,21.782499980926513,,-3.1536582759196166,2.628256367638427,,42.042041193165915,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-25,21.649999618530273,22.049999237060547,20.700000762939453,21.0,46764,0.0,0.0,22.114999961853027,21.803749990463256,,-5.04182665058255,1.4275066056339305,,35.28643984072541,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-26,21.100000381469727,21.25,20.600000381469727,20.649999618530273,16217,0.0,0.0,21.829999923706055,21.803749990463256,,-5.40540682226193,0.12039182826018471,,32.27872479077186,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-29,20.649999618530273,20.649999618530273,19.899999618530273,20.25,17533,0.0,0.0,21.604999923706053,21.791249990463257,,-6.271696035598138,-0.8547011614235724,,29.21397360934938,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-30,20.0,20.450000762939453,19.799999237060547,19.979999542236328,18884,0.0,0.0,21.367999839782716,21.779499959945678,,-6.495695937633915,-1.889391955369708,,27.327834673396055,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-08-31,20.450000762939453,20.850000381469727,19.979999542236328,20.0,18446,0.0,0.0,21.107999801635742,21.760749959945677,,-5.2491937277253475,-2.9996675643598296,,27.700209407287943,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-01,20.0,20.899999618530273,19.0,19.979999542236328,16258,0.0,0.0,20.905999755859376,21.7427499294281,,-4.429351499267649,-3.848410050635822,,27.548193194483773,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-02,20.200000762939453,20.850000381469727,19.979999542236328,20.350000381469727,12807,0.0,0.0,20.755999755859374,21.738999938964845,,-1.956057906943437,-4.521827985948644,,34.68890163227945,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-05,19.360000610351562,20.450000762939453,19.1200008392334,20.049999237060547,17797,0.0,0.0,20.570999717712404,21.707749938964845,,-2.532694024604239,-5.236610079112826,,31.940159224419162,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-06,20.850000381469727,20.850000381469727,19.100000381469727,20.0,22341,0.0,0.0,20.390999794006348,21.6802499294281,,-1.917511637272816,-5.9466571631711895,,31.4922679707917,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-07,20.0,20.0,19.299999237060547,19.979999542236328,29177,0.0,0.0,20.223999786376954,21.657249927520752,,-1.2064885616987904,-6.617876904687278,,31.30317077997269,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-08,19.959999084472656,20.0,19.219999313354492,19.899999618530273,31572,0.0,0.0,20.11399974822998,21.63849992752075,,-1.06393622540707,-7.04531360490405,,30.51392275850384,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-09,19.360000610351562,19.959999084472656,19.360000610351562,19.8799991607666,7511,0.0,0.0,20.036999702453613,21.617999887466432,,-0.7835531467707033,-7.313350880020324,,30.308182109413877,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-12,19.959999084472656,19.959999084472656,19.0,19.31999969482422,47684,0.0,0.0,19.943999671936034,21.58724989891052,,-3.1287604661860744,-7.61213324842003,,25.187385635853758,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-13,19.31999969482422,19.780000686645508,18.899999618530273,19.299999237060547,17656,0.0,0.0,19.875999641418456,21.54724988937378,,-2.897969484551686,-7.756211379808225,,25.02476165677865,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-14,19.18000030517578,19.739999771118164,19.15999984741211,19.479999542236328,20360,0.0,0.0,19.82399959564209,21.5104998588562,,-1.7352706841326941,-7.840358310035985,,29.4402286763698,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-15,19.760000228881836,20.799999237060547,19.459999084472656,19.600000381469727,14831,0.0,0.0,19.78599967956543,21.481749868392946,,-0.9400550950569252,-7.893910874190702,,32.302603367747565,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-16,20.799999237060547,20.799999237060547,19.020000457763672,19.479999542236328,23871,0.0,0.0,19.69899959564209,21.433749866485595,,-1.1117318539069836,-8.093545374232484,,30.95046486891637,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-19,20.950000762939453,20.950000762939453,19.100000381469727,19.420000076293945,26451,0.0,0.0,19.63599967956543,21.38049988746643,,-1.1000183682843934,-8.159305054058413,,30.26825373299009,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-20,19.1200008392334,19.280000686645508,18.8799991607666,19.219999313354492,11032,0.0,0.0,19.55799961090088,21.323499870300292,,-1.7281946225113858,-8.279598893887162,,28.04885318902373,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-21,19.5,19.5,18.700000762939453,19.0,16189,0.0,0.0,19.459999656677248,21.260999870300292,,-2.3638215045877935,-8.470910232866707,,25.807223064959146,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-22,19.299999237060547,19.299999237060547,18.0,18.219999313354492,68633,0.0,0.0,19.29199962615967,21.181499862670897,,-5.556709172602097,-8.920521439754976,,19.773442910005443,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-23,18.479999542236328,18.700000762939453,17.479999542236328,18.219999313354492,61878,0.0,0.0,19.125999641418456,21.100749826431276,,-4.737009019397701,-9.358673038904062,,19.773442910005443,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-26,18.239999771118164,19.0,17.8799991607666,18.459999084472656,12639,0.0,0.0,19.039999580383302,21.012249803543092,,-3.0462211591024086,-9.386192538160424,,25.95147064339912,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-27,18.459999084472656,18.579999923706055,17.520000457763672,17.799999237060547,22699,0.0,0.0,18.8899995803833,20.882249784469604,,-5.77025075455632,-9.540400218600803,,21.13208446793722,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-28,18.479999542236328,19.440000534057617,17.5,18.8799991607666,196164,0.0,0.0,18.82999954223633,20.766749763488768,,0.2655317033764189,-9.326207727785848,,40.57844520538827,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-29,18.8799991607666,18.8799991607666,17.959999084472656,18.479999542236328,27354,0.0,0.0,18.71799945831299,20.63624973297119,,-1.2715029541843492,-9.29553721960126,,36.94503376953006,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-09-30,18.5,18.84000015258789,18.0,18.84000015258789,32792,0.0,0.0,18.653999519348144,20.502249717712402,,0.9971085988654862,-9.014865313866064,,41.98030597676215,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-03,18.81999969482422,19.68000030517578,17.780000686645508,18.5,39178,0.0,0.0,18.56199951171875,20.372249698638917,,-0.3340131093075782,-8.885862944440113,,38.82678553066141,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-04,18.0,19.68000030517578,18.0,18.979999542236328,86479,0.0,0.0,18.537999534606932,20.25799970626831,,2.3842918261178383,-8.490473870078938,,45.09713121162368,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-05,18.979999542236328,18.979999542236328,18.1200008392334,18.559999465942383,44983,0.0,0.0,18.493999481201172,20.133249711990356,,0.3568724266933108,-8.1420051618042,,41.12495215620005,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-06,18.5,18.780000686645508,17.959999084472656,18.399999618530273,24031,0.0,0.0,18.51199951171875,20.008249711990356,,-0.605012403536286,-7.478166365421501,,39.690706276321954,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-07,18.399999618530273,19.0,18.200000762939453,18.8799991607666,30744,0.0,0.0,18.57799949645996,19.89274969100952,,1.6255768785233746,-6.609192871630806,,45.79788180320844,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-10,18.8799991607666,19.239999771118164,18.219999313354492,18.739999771118164,13840,0.0,0.0,18.605999565124513,19.798749685287476,,0.7201989096292563,-6.024370928075824,,44.3860824525871,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-11,18.719999313354492,18.719999313354492,18.0,18.5,2392,0.0,0.0,18.675999641418457,19.702499675750733,,-0.9423840479635484,-5.2099989911212266,,41.99604166564782,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-12,18.479999542236328,18.5,17.899999618530273,18.5,4552,0.0,0.0,18.637999725341796,19.59999966621399,,-0.7404213294099371,-4.908163047219157,,41.99604166564782,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-13,18.479999542236328,18.479999542236328,17.959999084472656,18.1200008392334,7382,0.0,0.0,18.601999855041505,19.502999687194823,,-2.591113963897144,-4.619801295207379,,38.21720124027184,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-14,18.1200008392334,18.399999618530273,18.1200008392334,18.15999984741211,4661,0.0,0.0,18.533999824523924,19.410749673843384,,-2.017912920323564,-4.516826315579704,,38.841024644100564,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-17,18.15999984741211,19.440000534057617,18.0,19.219999313354492,18187,0.0,0.0,18.605999755859376,19.343749666213988,,3.300008414230773,-3.8138929787908413,,52.522257971597575,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-18,19.440000534057617,19.440000534057617,18.3799991607666,19.18000030517578,58341,0.0,0.0,18.62599983215332,19.27824969291687,,2.97433951473635,-3.3833458490954045,,52.04909959887591,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-19,18.299999237060547,19.18000030517578,18.299999237060547,18.780000686645508,36417,0.0,0.0,18.647999954223632,19.20649971961975,,0.7078546372045574,-2.9078685525692167,,47.445928392294036,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-20,18.100000381469727,18.739999771118164,17.700000762939453,18.0,52642,0.0,0.0,18.607999992370605,19.13149971961975,,-3.267411826203184,-2.736323523619456,,40.014368740802404,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-21,17.600000381469727,18.559999465942383,17.600000381469727,18.18000030517578,22038,0.0,0.0,18.538000106811523,19.069749736785887,,-1.9311673296635719,-2.7884457704686563,,42.26190351919949,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-24,18.940000534057617,18.979999542236328,18.040000915527344,18.040000915527344,38682,0.0,0.0,18.468000221252442,19.014499759674074,,-2.3175184134585893,-2.874119989107718,,40.97594847446835,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-25,18.399999618530273,18.399999618530273,17.920000076293945,17.920000076293945,22143,0.0,0.0,18.410000228881835,18.962999773025512,,-2.6615977539162166,-2.916202872766514,,39.85646337846146,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-26,18.0,18.5,17.940000534057617,18.479999542236328,21615,0.0,0.0,18.408000183105468,18.92499976158142,,0.39113080407799977,-2.7318340025846943,,47.11736276811779,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-27,18.399999618530273,19.0,18.0,19.0,79971,0.0,0.0,18.49600009918213,18.900499773025512,,2.724912943962174,-2.1401533224040867,,52.81396316227932,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-28,19.0,19.459999084472656,18.200000762939453,19.399999618530273,35785,0.0,0.0,18.620000076293945,18.876749753952026,,4.18904156305233,-1.360137105193805,,56.67971924296071,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-10-31,19.459999084472656,19.459999084472656,18.559999465942383,18.84000015258789,21045,0.0,0.0,18.582000160217284,18.84649977684021,,1.3884403731895676,-1.4034415926291086,,50.44838646798708,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-01,18.84000015258789,18.84000015258789,18.200000762939453,18.399999618530273,14794,0.0,0.0,18.504000091552733,18.806499767303468,,-0.5620431934062561,-1.608484723333011,,46.1547982958499,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-02,18.5,20.950000762939453,18.31999969482422,20.399999618530273,105739,0.0,0.0,18.665999984741212,18.816999769210817,,9.289615532018344,-0.802464719783208,,61.990227812437425,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-03,20.399999618530273,20.5,19.540000915527344,20.5,45729,0.0,0.0,18.915999984741212,18.83199977874756,,8.373863483487723,0.4460503769145662,,62.58275863850726,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-04,21.549999237060547,24.0,21.549999237060547,22.700000762939453,127801,0.0,0.0,19.368000030517578,18.90249981880188,,17.203638616128362,2.462638360946722,,72.67489958474998,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-07,23.350000381469727,24.799999237060547,22.700000762939453,23.600000381469727,147489,0.0,0.0,19.923999977111816,19.00949983596802,,18.45011247029114,4.8107533024801885,,75.57701369687862,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-08,24.0,24.700000762939453,23.5,24.399999618530273,80099,0.0,0.0,20.571999931335448,19.13699984550476,,18.607814991113155,7.498563502197893,,77.83090333210271,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-09,24.399999618530273,24.5,23.5,23.649999618530273,48590,0.0,0.0,21.088999938964843,19.24124984741211,,12.143770150208164,9.603066880820373,,71.19724019453133,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-10,23.649999618530273,24.200000762939453,23.299999237060547,23.5,28945,0.0,0.0,21.538999938964842,19.338749837875366,,9.104415555931343,11.37741642833726,,69.913793647701,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-11,23.5,23.5,23.049999237060547,23.299999237060547,38815,0.0,0.0,21.92899990081787,19.43424983024597,,6.2519920764445915,12.836873521556068,,68.14976683585977,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-14,23.450000762939453,24.149999618530273,23.149999618530273,24.0,86034,0.0,0.0,22.44499988555908,19.54874982833862,,6.928046880683623,14.815525712145252,,70.91576276288603,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-15,24.399999618530273,24.5,23.850000381469727,24.5,53835,0.0,0.0,23.054999923706056,19.68074984550476,,6.267621258190238,17.144926411287127,,72.73700871436641,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-16,24.5,25.399999618530273,24.100000381469727,25.350000381469727,66931,0.0,0.0,23.55,19.839499855041502,,7.643313721739813,18.70258913818136,,75.54103914524487,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-17,25.0,25.5,24.649999618530273,24.950000762939453,55400,0.0,0.0,23.995000076293945,20.00774989128113,,3.9799986814295085,19.928528728512134,,71.79863614746539,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-18,24.899999618530273,25.299999237060547,24.899999618530273,25.149999618530273,36529,0.0,0.0,24.239999961853027,20.18099989891052,,3.7541240021012023,20.112977965782715,,72.53138800703148,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-21,25.299999237060547,25.5,25.0,25.25,36673,0.0,0.0,24.404999923706054,20.350749921798705,,3.462405568266961,19.921870287269556,,72.91039594354002,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-22,25.25,25.450000762939453,25.049999237060547,25.25,23061,0.0,0.0,24.489999961853027,20.536999940872192,,3.1033076330371228,19.248186358094486,,72.91039594354001,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-23,25.25,25.25,24.549999237060547,25.200000762939453,6882,0.0,0.0,24.645000076293947,20.694999980926514,,2.251980868035631,19.086736404967088,,72.33167235631336,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-24,25.200000762939453,25.850000381469727,24.899999618530273,25.25,47813,0.0,0.0,24.820000076293944,20.864249992370606,,1.7324734987279762,18.95946456436167,,72.56617769348412,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-25,25.25,25.700000762939453,25.149999618530273,25.200000762939453,39563,0.0,0.0,25.010000228881836,21.023250007629393,,0.7596982499752335,18.96352951996309,,71.90981681545709,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-28,25.0,25.399999618530273,24.450000762939453,24.899999618530273,35017,0.0,0.0,25.100000190734864,21.183249998092652,,-0.7968150226485518,18.489845481665363,,67.93906949845456,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-29,24.899999618530273,25.5,24.899999618530273,24.950000762939453,16714,0.0,0.0,25.14500026702881,21.33250002861023,,-0.7755001074509742,17.871792960531668,,68.25371296893967,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-11-30,25.399999618530273,25.399999618530273,24.899999618530273,25.350000381469727,51144,0.0,0.0,25.14500026702881,21.502250051498415,,0.815271872196884,16.941251296054688,,70.72857389454444,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-01,25.350000381469727,25.399999618530273,25.0,25.25,18114,0.0,0.0,25.175000190734863,21.673500061035156,,0.29791383792218934,16.155674532673846,,69.27459330750595,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-02,25.299999237060547,25.5,25.0,25.25,16454,0.0,0.0,25.185000228881837,21.83275008201599,,0.25808922186795313,15.354227636339552,,69.27459330750595,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-05,25.25,27.450000762939453,25.25,26.899999618530273,79576,0.0,0.0,25.350000190734864,22.036750078201294,,6.11439611886834,15.035112259184851,,77.94905403944395,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-06,19.979999542236328,20.649999618530273,15.800000190734863,17.200000762939453,2712632,0.0,0.0,24.545000267028808,22.00425009727478,,-29.924625887887483,11.546633757215377,,27.964970511750565,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-07,17.0,17.200000762939453,15.640000343322754,15.84000015258789,485670,0.0,0.0,23.609000205993652,21.937750101089478,,-32.90694220686836,7.618147244831533,,25.49636727223134,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-08,16.219999313354492,16.299999237060547,15.859999656677246,16.0,149257,0.0,0.0,22.68400020599365,21.884750080108642,,-29.46570333845959,3.652087060438764,,26.32040914975734,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-09,16.0,16.260000228881836,15.15999984741211,15.880000114440918,356018,0.0,0.0,21.7520001411438,21.827750086784363,20.990333263079325,-26.995218778047096,-0.34703506013854424,3.989535626754441,26.087359792975263,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-12,15.84000015258789,15.859999656677246,15.220000267028809,15.479999542236328,114145,0.0,0.0,20.810000133514404,21.734250092506407,20.944333259264628,-25.61268888554275,-4.252504480523434,3.771506227787716,25.28372129902739,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-13,15.520000457763672,15.800000190734863,15.119999885559082,15.140000343322754,101840,0.0,0.0,19.829000091552736,21.633250093460084,20.8921665986379,-23.647182039338038,-8.340170774676103,3.5471835404112704,24.590301214980443,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-14,15.119999885559082,15.300000190734863,14.640000343322754,15.079999923706055,85179,0.0,0.0,18.802000045776367,21.540750074386597,20.84324992497762,-19.79576700887421,-12.714274197288924,3.3464078390823513,24.462797564051854,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-15,15.100000381469727,15.319999694824219,14.800000190734863,14.800000190734863,34091,0.0,0.0,17.757000064849855,21.46075007915497,20.79866659641266,-16.652586942140076,-17.258250530127565,3.1832977353293734,23.841526895053434,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-16,15.0,15.100000381469727,14.359999656677246,14.399999618530273,112699,0.0,0.0,16.672000026702882,21.36625006198883,20.746583263079327,-13.627641581895608,-21.970397340042144,2.986837837593544,22.94502553411563,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-19,14.399999618530273,14.680000305175781,14.020000457763672,14.079999923706055,85604,0.0,0.0,15.390000057220458,21.2672500371933,20.69099992911021,-8.512021628614592,-27.6352136251485,2.7850278384678906,22.225025061079535,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-20,14.020000457763672,14.100000381469727,13.640000343322754,13.800000190734863,43111,0.0,0.0,15.05,21.16425004005432,20.635583257675172,-8.30564657319028,-28.88951901665695,2.5619182931624476,21.5867266476765,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-21,13.979999542236328,14.0600004196167,13.819999694824219,13.859999656677246,35633,0.0,0.0,14.851999950408935,21.048750042915344,20.578166588147482,-6.679237119876068,-29.439990877710727,2.2868094334453803,22.10299643293095,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-22,13.859999656677246,14.859999656677246,13.539999961853027,14.619999885559082,74019,0.0,0.0,14.713999938964843,20.939250040054322,20.52749991416931,-0.6388477218681713,-29.730052839434588,2.0058464382250265,28.52258214334003,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-23,14.619999885559082,15.220000267028809,14.300000190734863,14.479999542236328,28868,0.0,0.0,14.573999881744385,20.816250038146972,20.477333243687948,-0.6449865532509226,-29.987390355915718,1.6550826732455206,28.063772682756777,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-27,14.479999542236328,14.680000305175781,13.9399995803833,13.9399995803833,41596,0.0,0.0,14.419999885559083,20.693750023841858,20.415999913215636,-3.3287122675810736,-30.31712536903466,1.3604531338503267,26.306057129505177,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-28,13.9399995803833,14.34000015258789,13.579999923706055,13.619999885559082,66646,0.0,0.0,14.267999839782714,20.57425003051758,20.353666575749717,-4.541631353378964,-30.65117893182433,1.083752914723852,25.294995415709394,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-29,13.899999618530273,14.279999732971191,13.5,13.979999542236328,64881,0.0,0.0,14.157999801635743,20.41375002861023,20.295999908447264,-1.2572415729151905,-30.64478705875669,0.5801641736998565,28.618854657870813,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2022-12-30,15.119999885559082,15.479999542236328,14.520000457763672,14.9399995803833,179602,0.0,0.0,14.171999740600587,20.27475001811981,20.248416574796043,5.419135293818228,-30.10024918711755,0.13005186468035382,36.70623230270138,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-02,14.960000038146973,15.920000076293945,14.960000038146973,15.260000228881836,261267,0.0,0.0,14.257999801635743,20.08875000476837,20.203083237012226,7.027636703509699,-29.024952780778353,-0.56591972078002,39.17986866418135,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-03,15.399999618530273,15.680000305175781,14.800000190734863,14.800000190734863,50869,0.0,0.0,14.329999828338623,19.86875,20.155166578292846,3.279835087414166,-27.876691647241902,-1.4210578572013322,36.94465901948548,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-04,15.5,15.579999923706055,14.100000381469727,14.100000381469727,99310,0.0,0.0,14.359999847412109,19.611250019073488,20.098499917984007,-1.81058125839213,-26.776723393736372,-2.424309778833452,33.78590650845533,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-05,14.5,14.5,14.039999961853027,14.039999961853027,24094,0.0,0.0,14.377999877929687,19.371000027656557,20.040916577974954,-2.3508131794846627,-25.77564474006615,-3.342744069174154,33.52134514228156,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-09,14.100000381469727,14.720000267028809,14.079999923706055,14.300000190734863,55043,0.0,0.0,14.345999908447265,19.141000032424927,19.987166579564413,-0.3206449045445477,-25.05093838281654,-4.233549281590701,35.864981355270146,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-10,14.220000267028809,14.5,14.0600004196167,14.239999771118164,56167,0.0,0.0,14.32199993133545,18.914500045776368,19.92749991416931,-0.5725468552605938,-24.28031459106121,-5.083426785879225,35.55348327561407,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-11,14.880000114440918,14.880000114440918,14.220000267028809,14.220000267028809,35996,0.0,0.0,14.35,18.67000005245209,19.866416589419046,-0.9059214841197982,-23.13872544357442,-6.022306698250628,35.44298267226711,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-12,14.5,14.5,14.15999984741211,14.319999694824219,39384,0.0,0.0,14.419999980926514,18.415500044822693,19.80658325354258,-0.6934832609886734,-21.696397350988402,-7.023337598982804,36.50560961291333,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-13,14.5,14.680000305175781,14.140000343322754,14.300000190734863,49409,0.0,0.0,14.452000045776368,18.13925004005432,19.74658325513204,-1.0517565358431242,-20.327466604936394,-8.139804209723126,36.37664622984186,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-16,14.380000114440918,14.640000343322754,14.260000228881836,14.34000015258789,35374,0.0,0.0,14.392000102996827,17.87400002479553,19.687749926249186,-0.36131149275150454,-19.480809650712402,-9.212580961501482,36.85710523076037,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-17,14.34000015258789,14.640000343322754,14.039999961853027,14.15999984741211,33689,0.0,0.0,14.282000064849854,17.599250030517577,19.62699991861979,-0.8542236163267146,-18.84881435240435,-10.331430664441605,35.55588844182341,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-18,14.199999809265137,14.300000190734863,14.039999961853027,14.039999961853027,14545,0.0,0.0,14.20600004196167,17.319000029563902,19.560666584968565,-1.1685209039723425,-17.97447879374257,-11.460072414542745,34.67694379801071,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-19,14.039999961853027,14.180000305175781,13.819999694824219,13.859999656677246,42196,0.0,0.0,14.181999969482423,17.034250020980835,19.48449991544088,-2.270485922282286,-16.744206806788313,-12.575379943512402,33.34537771899613,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-20,13.84000015258789,14.319999694824219,13.699999809265137,14.079999923706055,89788,0.0,0.0,14.185999965667724,16.75625,19.405999914805093,-0.747215862245917,-15.339052797208666,-13.654281801699705,36.55218758726487,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-23,14.100000381469727,14.420000076293945,14.100000381469727,14.15999984741211,36524,0.0,0.0,14.17199993133545,16.4789999961853,19.326499907175698,-0.08467459766780466,-13.999636297007683,-14.733655471331126,37.72547500010978,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-24,13.859999656677246,14.15999984741211,13.859999656677246,14.020000457763672,23279,0.0,0.0,14.15,16.199499988555907,19.241666571299234,-0.9187246801153955,-12.651624988448843,-15.810307134627344,36.45500002682372,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-25,14.100000381469727,14.5,13.9399995803833,13.979999542236328,23817,0.0,0.0,14.125999927520752,15.92649998664856,19.16066656112671,-1.0335578793256321,-11.305057989119994,-16.879196577845832,36.0811135113526,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-26,14.0,14.479999542236328,14.0,14.199999809265137,37377,0.0,0.0,14.113999938964843,15.657749962806701,19.082749899228414,0.6093231590774739,-9.859335009876064,-17.948146648194548,39.74159560645461,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-27,14.300000190734863,15.199999809265137,14.100000381469727,14.899999618530273,161430,0.0,0.0,14.173999881744384,15.396499943733215,19.010666569073994,5.122052651636828,-7.940116691822678,-19.01125671847931,49.626464557160205,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-30,15.0,15.300000190734863,14.319999694824219,14.680000305175781,86673,0.0,0.0,14.207999897003173,15.13224995136261,18.937999908129374,3.3220749689909908,-6.107816467016599,-20.09583892295352,47.016061205093195,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-01-31,14.680000305175781,14.720000267028809,14.140000343322754,14.5,53403,0.0,0.0,14.241999912261964,14.86349995136261,18.862999908129375,1.8115439497784687,-4.181384203817148,-21.20288382678252,44.9334846212535,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-01,14.5,14.640000343322754,14.199999809265137,14.300000190734863,35631,0.0,0.0,14.267999935150147,14.548499965667725,18.7946665763855,0.2242798971836366,-1.9280340322336715,-22.59240191072534,42.671776858524346,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-02,14.600000381469727,14.600000381469727,14.300000190734863,14.5,27467,0.0,0.0,14.331999969482421,14.480999946594238,18.729249906539916,1.1722022807375565,-1.028934311589858,-22.682435127646333,45.61954878877261,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-03,14.5,14.579999923706055,14.0,14.199999809265137,78836,0.0,0.0,14.34399995803833,14.43999993801117,18.659249901771545,-1.0039051115061932,-0.6648198087600674,-22.61210920037998,42.12090502361938,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-06,14.5600004196167,14.5600004196167,14.0,14.100000381469727,66588,0.0,0.0,14.338000011444091,14.392499947547913,18.593416571617126,-1.6599220936281318,-0.37866900331729486,-22.593570191300493,40.992376593410135,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-07,14.15999984741211,14.399999618530273,13.960000038146973,14.260000228881836,52751,0.0,0.0,14.361999988555908,14.351999950408935,18.53016657034556,-0.7102058192128455,0.0696769661477628,-22.547917225002628,43.59630536350117,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-08,14.600000381469727,14.600000381469727,13.899999618530273,14.079999923706055,39009,0.0,0.0,14.372000026702882,14.31699995994568,18.464999906222026,-2.0317290735756797,0.384159159817521,-22.464121133727293,41.383774043587856,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-09,14.319999694824219,14.460000038146973,14.0600004196167,14.100000381469727,52458,0.0,0.0,14.36200008392334,14.290999960899352,18.400833249092102,-1.8242563774031197,0.4968170402228385,-22.335039030884808,41.73759174038712,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-10,14.4399995803833,14.479999542236328,14.0,14.180000305175781,75699,0.0,0.0,14.29000015258789,14.268499970436096,18.338583254814147,-0.769767993264772,0.150682848206479,-22.19409879064455,43.21410215851793,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-13,14.479999542236328,14.479999542236328,14.0600004196167,14.300000190734863,106648,0.0,0.0,14.2520001411438,14.255999970436097,18.282749923070273,0.3367951804357159,-0.028057164005276067,-22.02485933230964,45.44736459883574,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-14,14.460000038146973,15.239999771118164,14.34000015258789,14.760000228881836,179148,0.0,0.0,14.278000164031983,14.264999985694885,18.2336665948232,3.375823359801252,0.09113339186915256,-21.765598205327926,53.067077116961734,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-15,14.960000038146973,15.34000015258789,14.84000015258789,15.0,155023,0.0,0.0,14.348000144958496,14.287999987602234,18.189916594823202,4.544186286969056,0.4199339124322808,-21.450986797440528,56.482353781902546,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-16,15.100000381469727,15.5,14.819999694824219,15.5,53808,0.0,0.0,14.448000144958495,14.330499982833862,18.152583265304564,7.281283530500176,0.8199306532597178,-21.05531332158071,62.590072348343796,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-17,15.479999542236328,17.559999465942383,15.199999809265137,17.0,182603,0.0,0.0,14.728000164031982,14.40899999141693,18.127583265304565,15.426397410807931,2.213895293254717,-20.513397839439786,74.26110818568309,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-20,17.139999389648438,17.899999618530273,16.84000015258789,17.1200008392334,144234,0.0,0.0,15.03000020980835,14.471500015258789,18.10374994277954,13.905526282435755,3.859311017936474,-20.063522413871112,74.93481532663391,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-21,17.18000030517578,17.360000610351562,16.600000381469727,16.799999237060547,50726,0.0,0.0,15.28400011062622,14.529500007629395,18.074166599909464,9.918863618564924,5.192884150181629,-19.611784436566086,69.69590324988215,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-22,16.739999771118164,17.8799991607666,16.5,17.8799991607666,101706,0.0,0.0,15.664000034332275,14.627999997138977,18.056083265940348,14.147083258282114,7.08230815829864,-18.985752437616704,75.83608270948206,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-23,17.979999542236328,17.979999542236328,16.940000534057617,17.799999237060547,108078,0.0,0.0,16.033999919891357,14.732499980926514,18.037749926249187,11.014090844408308,8.834209676903683,-18.324070124249552,74.62981796656788,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-24,18.799999237060547,19.65999984741211,17.100000381469727,17.5,299351,0.0,0.0,16.36599988937378,14.820499992370605,18.017083263397218,6.928999867356178,10.42812251812541,-17.741957587112132,70.12521801307409,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-27,17.5,17.5,16.200000762939453,16.81999969482422,148015,0.0,0.0,16.617999839782716,14.86749999523163,17.99141659736633,1.2155485436816829,11.77400265755853,-17.363372057050782,61.11988070966745,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-02-28,16.81999969482422,16.81999969482422,15.899999618530273,16.360000610351562,80149,0.0,0.0,16.777999877929688,14.895000004768372,17.962083276112875,-2.4913533831167474,12.641825260547208,-17.075320407980215,55.891094144958,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-01,16.360000610351562,16.600000381469727,16.260000228881836,16.299999237060547,20400,0.0,0.0,16.907999801635743,14.932499980926513,17.93691660563151,-3.5959343015628367,13.229531714264608,-16.749905743341216,55.227409158779786,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-02,16.200000762939453,16.799999237060547,16.200000762939453,16.479999542236328,58917,0.0,0.0,17.005999755859374,14.991999959945678,17.913416608174643,-3.093027291393522,13.433830051324207,-16.308539638919576,56.881574840079296,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-03,16.479999542236328,17.0,16.260000228881836,16.8799991607666,112660,0.0,0.0,16.993999671936034,15.062999939918518,17.89174993832906,-0.6708280179485576,12.819489741217927,-15.810359568856816,60.38429311957095,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-06,16.899999618530273,17.1200008392334,16.639999389648438,16.65999984741211,22746,0.0,0.0,16.947999572753908,15.121999931335449,17.86724993387858,-1.6993139757024478,12.075120021887226,-15.364703648868689,57.61222804627858,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-07,16.600000381469727,16.84000015258789,16.360000610351562,16.600000381469727,40469,0.0,0.0,16.927999687194824,15.180999946594238,17.84324994087219,-1.9376140819119452,11.507804141666664,-14.920207939136343,56.84577009953532,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-08,17.0,17.0,16.399999618530273,16.399999618530273,16796,0.0,0.0,16.77999973297119,15.235499930381774,17.81808327039083,-2.264601433182695,10.137506544891664,-14.49417033705673,54.25469535888178,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-09,16.440000534057617,16.579999923706055,16.15999984741211,16.420000076293945,30672,0.0,0.0,16.641999816894533,15.287999939918517,17.794749943415322,-1.3339727379110946,8.856618801002114,-14.08702011249329,54.478152701945376,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-10,16.780000686645508,16.780000686645508,16.0,16.0,15274,0.0,0.0,16.49199981689453,15.330499935150147,17.769749943415324,-2.983263535999571,7.57639924762837,-13.726979929557498,49.05866821194507,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-13,16.020000457763672,16.1200008392334,15.34000015258789,15.699999809265137,71415,0.0,0.0,16.379999828338622,15.364499926567078,17.748749947547914,-4.151404311354356,6.609391172020006,-13.433340533991991,45.57140395542729,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-14,15.800000190734863,16.479999542236328,15.699999809265137,16.399999618530273,28855,0.0,0.0,16.383999729156493,15.420499920845032,17.733583283424377,0.09765557640548404,6.2481749181751685,-13.043519324948779,53.82006560841045,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-15,16.219999313354492,16.239999771118164,15.979999542236328,15.979999542236328,20023,0.0,0.0,16.351999759674072,15.468999910354615,17.712916620572408,-2.2749524394877976,5.70818963369698,-12.668250849279266,49.01981252985527,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-16,16.260000228881836,16.299999237060547,16.0,16.260000228881836,15127,0.0,0.0,16.32999982833862,15.528999924659729,17.700083295504253,-0.42865646168171023,5.158090717786156,-12.265950021805661,52.087845503738095,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-17,16.260000228881836,16.5,16.200000762939453,16.299999237060547,7742,0.0,0.0,16.271999835968018,15.58449990749359,17.678583296140037,0.1720710507299708,4.411434005295558,-11.845312226481806,52.52736359439018,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-20,16.299999237060547,16.3799991607666,15.619999885559082,15.9399995803833,11500,0.0,0.0,16.199999809265137,15.62899990081787,17.65741662979126,-1.6049397033519475,3.6534641504309286,-11.48761889409736,48.23831713438281,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-21,15.960000038146973,16.34000015258789,15.960000038146973,16.280000686645508,10379,0.0,0.0,16.167999839782716,15.685499906539917,17.636083300908407,0.6927316178418316,3.0760889746435534,-11.060184742198503,52.20747227796207,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-22,16.280000686645508,16.280000686645508,16.0,16.1200008392334,11574,0.0,0.0,16.13999996185303,15.738999938964843,17.616249974568685,-0.12391030152972958,2.547811325009505,-10.656354435898065,50.25453252282893,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-23,16.079999923706055,16.079999923706055,15.699999809265137,16.0,24274,0.0,0.0,16.09799995422363,15.783999943733216,17.59141664505005,-0.6087709933054084,1.9893563837415265,-10.274423815806857,48.78068198037595,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-24,16.079999923706055,16.18000030517578,15.699999809265137,16.079999923706055,14849,0.0,0.0,16.10599994659424,15.81349995136261,17.57074998219808,-0.16143066543149676,1.8496853709252647,-10.000996159047505,49.83689756067721,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-27,16.079999923706055,16.079999923706055,15.619999885559082,15.65999984741211,19612,0.0,0.0,16.101999950408935,15.837999939918518,17.547916650772095,-2.745001269147316,1.666877203509921,-9.744271897817235,44.63310089645269,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-28,15.65999984741211,16.200000762939453,14.619999885559082,14.880000114440918,52772,0.0,0.0,15.95,15.84749994277954,17.51458332538605,-6.708463232345338,0.6467900778706729,-9.518258879674278,36.922471179049204,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-29,14.640000343322754,15.0,14.260000228881836,14.899999618530273,79180,0.0,0.0,15.842000007629395,15.862499928474426,17.482583324114483,-5.9462213650136375,-0.12923512017316025,-9.266842122842371,37.221938985375324,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-30,15.979999542236328,15.979999542236328,15.0,15.359999656677246,12716,0.0,0.0,15.751999950408935,15.883999919891357,17.456416654586793,-2.4885747521952757,-0.831024742811285,-9.007671882546825,43.8276747364654,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-03-31,15.979999542236328,15.979999542236328,14.680000305175781,14.800000190734863,49827,0.0,0.0,15.602000045776368,15.8989999294281,17.425583322842915,-5.140365675480271,-1.8680412917167426,-8.760587035348427,38.51452265686704,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-03,14.899999618530273,15.0,14.479999542236328,14.579999923706055,15488,0.0,0.0,15.466000080108643,15.91099991798401,17.39608331521352,-5.728696183973924,-2.796806235743793,-8.53688367847003,36.63552386178119,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-04,14.579999923706055,14.819999694824219,14.15999984741211,14.479999542236328,64302,0.0,0.0,15.285999965667724,15.916499900817872,17.365416646003723,-5.272801421180613,-3.9612976413096295,-8.343691226776803,35.781012695646055,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-05,14.380000114440918,14.600000381469727,14.239999771118164,14.600000381469727,36567,0.0,0.0,15.133999919891357,15.929499912261964,17.326916654904682,-3.52847589036768,-4.99387926019108,-8.065005277480548,37.660107514341995,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-06,14.600000381469727,14.600000381469727,14.300000190734863,14.579999923706055,47095,0.0,0.0,14.991999912261964,15.94149990081787,17.288583318392437,-2.7481322769948386,-5.956152146682215,-7.791751312216968,37.46334961222371,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-11,15.0,15.0,14.100000381469727,14.4399995803833,95868,0.0,0.0,14.827999877929688,15.94799988269806,17.25241664250692,-2.6166731908589735,-7.022824260134692,-7.560777060038104,36.04378593666898,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-12,14.5,14.680000305175781,14.180000305175781,14.279999732971191,30262,0.0,0.0,14.689999866485596,15.947499871253967,17.221416640281678,-2.791015229685584,-7.885248565106227,-7.397282091462564,34.43773963351268,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-13,14.600000381469727,14.920000076293945,14.399999618530273,14.399999618530273,54754,0.0,0.0,14.641999816894531,15.938499855995179,17.18991663455963,-1.6527810503386828,-8.134391886404394,-7.279946756975705,36.71531233138303,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-14,14.5,14.5600004196167,14.020000457763672,14.199999809265137,23809,0.0,0.0,14.571999835968018,15.918499851226807,17.15791662534078,-2.55284127704061,-8.45871173692926,-7.223585480555713,34.56039571758362,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-17,14.199999809265137,14.479999542236328,14.199999809265137,14.260000228881836,25824,0.0,0.0,14.461999893188477,15.887499856948853,17.127416626612344,-1.3967616221721961,-8.972462480538708,-7.239368298759811,35.778193419613075,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-18,14.4399995803833,14.4399995803833,14.0,14.359999656677246,7749,0.0,0.0,14.417999839782714,15.821499848365784,17.093083294232688,-0.40227620855863794,-8.870840451501431,-7.439169539973775,37.85394770203341,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-19,14.279999732971191,14.34000015258789,14.100000381469727,14.15999984741211,5996,0.0,0.0,14.37599983215332,15.747499823570251,17.052749959627786,-1.502504085024447,-8.709318982586192,-7.654191489042534,35.39021612870411,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-20,14.15999984741211,14.359999656677246,13.880000114440918,14.199999809265137,33923,0.0,0.0,14.347999858856202,15.682499837875366,17.009416627883912,-1.0315030042303295,-8.50948504903641,-7.801071718316914,36.2834174659043,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-21,13.920000076293945,14.239999771118164,13.899999618530273,14.220000267028809,27328,0.0,0.0,14.30999984741211,15.590999865531922,16.970916628837585,-0.628927891984409,-8.216278809364917,-8.13106795281087,36.75422955496017,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-24,13.920000076293945,14.640000343322754,13.920000076293945,14.619999885559082,13635,0.0,0.0,14.313999843597411,15.511499881744385,16.939416631062826,2.1377675374122846,-7.720078956106116,-8.429550913223215,45.437679213795754,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-25,14.619999885559082,14.619999885559082,14.319999694824219,14.5,11583,0.0,0.0,14.319999885559081,15.436499881744385,16.890249967575073,1.25698404943731,-7.2328572198267995,-8.607037128648264,43.507784101109145,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-26,14.5,14.979999542236328,14.220000267028809,14.979999542236328,6363,0.0,0.0,14.389999866485596,15.390499877929688,16.844249963760376,4.100067277449012,-6.500763583896527,-8.63054210759377,52.24513642646206,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-27,14.960000038146973,14.960000038146973,14.199999809265137,14.520000457763672,13326,0.0,0.0,14.401999950408936,15.344499874114991,16.776083294550578,0.8193341741497908,-6.142265511670285,-8.533478257708769,45.053601710700825,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-04-28,14.399999618530273,14.479999542236328,14.119999885559082,14.220000267028809,24122,0.0,0.0,14.403999996185302,15.292499899864197,16.697916626930237,-1.2774210580756955,-5.810037008316639,-8.416719034273997,41.08190952523696,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-02,14.220000267028809,14.399999618530273,13.920000076293945,14.140000343322754,36108,0.0,0.0,14.392000007629395,15.233999919891357,16.612416632970174,-1.7509704292179882,-5.52710986405182,-8.29750868602172,40.067550756013816,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-03,14.140000343322754,14.380000114440918,13.880000114440918,13.880000114440918,17417,0.0,0.0,14.344000053405761,15.158999943733216,16.530999970436095,-3.2348015702542714,-5.376343382495878,-8.299558581795132,36.88038092933794,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-04,14.100000381469727,14.359999656677246,14.020000457763672,14.34000015258789,12113,0.0,0.0,14.36200008392334,15.10099995136261,16.454666638374327,-0.15318152908295368,-4.893714785904546,-8.226643035446239,45.1876728413621,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-05,14.380000114440918,14.899999618530273,14.300000190734863,14.779999732971191,11803,0.0,0.0,14.420000076293945,15.055499935150147,16.383666642506917,2.4965301995322102,-4.221047866849622,-8.106651193151615,51.731581779675665,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-08,14.779999732971191,15.0,14.520000457763672,14.979999542236328,22568,0.0,0.0,14.496000003814697,15.019999933242797,16.308499972025555,3.3388489120741207,-3.4886813033092317,-7.900788184032616,54.39670464371941,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-09,14.979999542236328,15.699999809265137,14.960000038146973,15.260000228881836,41756,0.0,0.0,14.560000038146972,14.990999937057495,16.231499973932902,4.807693605088421,-2.8750577060913622,-7.642547139005003,57.90129381906832,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-10,15.5,15.680000305175781,15.100000381469727,15.539999961853027,9661,0.0,0.0,14.664000034332275,14.97949993610382,16.149749970436098,5.973812912369109,-2.1062111760561693,-7.246242427743765,61.119103562228524,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-11,15.539999961853027,15.600000381469727,14.859999656677246,15.300000190734863,22103,0.0,0.0,14.696000099182129,14.969499945640564,16.06933329900106,4.1099624896324585,-1.8270473125462285,-6.844299840546997,57.09103006631896,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-12,15.5,15.5,14.880000114440918,15.0,26605,0.0,0.0,14.744000053405761,14.934499955177307,15.98474996884664,1.7362991431562322,-1.2755693350516584,-6.570324939183969,52.438727601927575,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-15,15.0,15.699999809265137,14.920000076293945,15.300000190734863,18579,0.0,0.0,14.852000045776368,14.91749997138977,15.901833303769429,3.0164297305257435,-0.43908111774106934,-6.1900619480543115,56.275853813407394,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-16,16.200000762939453,16.200000762939453,15.5,15.5,57559,0.0,0.0,14.988000011444091,14.898499965667725,15.82058330376943,3.4160661073189944,0.6007319259161108,-5.828377629300235,58.66979206357142,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-17,15.5,15.779999732971191,15.380000114440918,15.779999732971191,24396,0.0,0.0,15.17799997329712,14.885499978065491,15.74208329518636,3.9662653889391186,1.9649994670158277,-5.4413593236595075,61.82134730260743,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-19,16.299999237060547,16.299999237060547,15.5,15.5,39685,0.0,0.0,15.29399995803833,14.874499988555907,15.660833295186361,1.3469337160119332,2.8202626629814564,-5.021018306044718,57.12991359427084,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-22,15.5,15.960000038146973,15.140000343322754,15.380000114440918,23319,0.0,0.0,15.353999996185303,14.851999974250793,15.578999956448873,0.1693377508276319,3.3800163129870544,-4.666538187498622,55.19666434767672,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-23,15.380000114440918,15.380000114440918,14.760000228881836,14.9399995803833,21328,0.0,0.0,15.35,14.82249994277954,15.495999956130982,-2.671012505646247,3.5587792832302867,-4.3462830101840035,48.69049283310531,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-24,15.0,15.199999809265137,14.5,15.020000457763672,20820,0.0,0.0,15.326000022888184,14.797999954223632,15.413249953587849,-1.9966042324646092,3.5680502115007138,-3.9916954647257934,49.84800904656084,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-25,15.300000190734863,16.5,15.0,16.5,32789,0.0,0.0,15.42200002670288,14.808499956130982,15.339499950408936,6.990014080084193,4.142891396085656,-3.461651266303487,65.39928004830475,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-26,16.5,17.479999542236328,15.600000381469727,16.959999084472656,102787,0.0,0.0,15.58799991607666,14.840999937057495,15.270416609446208,8.801637001428176,5.0333534275809155,-2.812082233061528,68.6528207765167,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-29,16.959999084472656,17.360000610351562,16.420000076293945,16.84000015258789,16183,0.0,0.0,15.771999931335449,14.889999938011169,15.20033327738444,6.771495218755126,5.923438529188385,-2.041621941507,66.88592494622284,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-30,17.299999237060547,17.299999237060547,16.399999618530273,16.719999313354492,8963,0.0,0.0,15.913999843597413,14.935499930381775,15.115499941507975,5.06471960335825,6.551504253467769,-1.1908306825625425,65.08205426966552,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-05-31,16.719999313354492,16.719999313354492,15.979999542236328,16.559999465942383,26288,0.0,0.0,16.01999979019165,14.965499925613404,15.110166597366334,3.3707845369720295,7.046205404561688,-0.9574128175274039,62.65571611196029,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-01,16.0,16.940000534057617,16.0,16.420000076293945,11562,0.0,0.0,16.083999824523925,15.00599992275238,15.114999930063883,2.0890341670963406,7.183792531792972,-0.7211379941504361,60.529306007724166,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-02,16.399999618530273,16.700000762939453,16.059999465942383,16.3799991607666,16557,0.0,0.0,16.171999740600587,15.050999903678894,15.118166589736939,1.2861700686515738,7.448009063156579,-0.4442779860862292,59.90374627561482,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-05,16.239999771118164,16.280000686645508,15.619999885559082,16.0,7711,0.0,0.0,16.233999729156494,15.088999915122987,15.119166588783264,-1.4414175992391283,7.5883081746586045,-0.1995260352687533,54.17571797024423,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-07,16.0,16.600000381469727,15.699999809265137,16.600000381469727,21533,0.0,0.0,16.399999809265136,15.138999915122985,15.128499929110209,1.219515698357513,8.329479498064364,0.06940533471248221,60.58445282919647,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-08,16.600000381469727,16.84000015258789,16.0,16.479999542236328,9907,0.0,0.0,16.5459997177124,15.186499905586242,15.139666589101155,-0.39888901608901084,8.952028581820079,0.30934179566940506,58.812850255329714,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-09,16.479999542236328,16.780000686645508,16.0,16.0,14406,0.0,0.0,16.4959997177124,15.22549991607666,15.147333256403606,-3.0067878649381075,8.344552288192618,0.5160423841603269,52.23333239895414,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-12,16.0,16.5,15.619999885559082,16.18000030517578,24599,0.0,0.0,16.417999839782716,15.272999930381776,15.15883325735728,-1.4496256360670352,7.496889377464427,0.753136280914531,54.29810920258754,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-13,16.18000030517578,16.760000228881836,16.0,16.1200008392334,58981,0.0,0.0,16.345999908447265,15.315999960899353,15.173166600863139,-1.382595561480916,6.72499314558258,0.9413549840551313,53.46844086720985,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-14,16.299999237060547,17.5,16.200000762939453,16.5,126552,0.0,0.0,16.323999977111818,15.373499965667724,15.193333268165588,1.078167257626532,6.1827171012896285,1.1858273251968812,57.86014232210844,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-15,16.5,16.5,16.0,16.0,72343,0.0,0.0,16.268000030517577,15.416999959945679,15.211666599909465,-1.6474061348342037,5.519881123323919,1.3498413121770352,51.034810618617264,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-16,16.8799991607666,16.8799991607666,15.079999923706055,16.0,80120,0.0,0.0,16.226000022888183,15.457999968528748,15.22949993610382,-1.3928264672093567,4.968301565034427,1.5003777759191779,51.034810618617264,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-19,16.0,16.200000762939453,15.600000381469727,15.779999732971191,31115,0.0,0.0,16.166000080108642,15.498499965667724,15.23916660149892,-2.387729464460428,4.30686915456053,1.7017555549480992,48.13715194629512,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-20,15.779999732971191,16.079999923706055,15.539999961853027,16.0,82275,0.0,0.0,16.166000080108642,15.543499970436097,15.251833271980285,-1.0268469583449755,4.004890216853008,1.9123386235256286,51.125607329576,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-21,16.0,16.700000762939453,15.800000190734863,16.079999923706055,59518,0.0,0.0,16.114000034332275,15.589999961853028,15.269666608174642,-0.21099733494960785,3.3611294019333915,2.097841176878707,52.20413620510822,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-22,16.260000228881836,16.719999313354492,16.0,16.239999771118164,51651,0.0,0.0,16.090000057220458,15.630499958992004,15.291499940554301,0.9322542782117237,2.9397658388022916,2.2169180247560134,54.372784132915505,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-26,16.299999237060547,16.8799991607666,15.920000076293945,16.280000686645508,60510,0.0,0.0,16.11800012588501,15.674999976158142,15.310666616757711,1.0050909510810135,2.826157259334463,2.3796048109470567,54.92344535855436,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-27,16.280000686645508,17.059999465942383,16.020000457763672,16.3799991607666,58929,0.0,0.0,16.138000011444092,15.7099999666214,15.322666613260905,1.4995609688368983,2.7243796672950475,2.527845597223132,56.34195704050849,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-28,16.899999618530273,16.899999618530273,16.459999084472656,16.540000915527344,42535,0.0,0.0,16.180000019073486,15.760499978065491,15.333333285649617,2.224974635534474,2.6617178490011693,2.7858697418105214,58.58754090242317,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-29,16.540000915527344,16.959999084472656,16.299999237060547,16.700000762939453,58258,0.0,0.0,16.200000095367432,15.822499990463257,15.349166623751323,3.0864238557319608,2.385843609617363,3.0837724178425243,60.76105206776873,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-06-30,16.920000076293945,17.079999923706055,16.260000228881836,16.780000686645508,32325,0.0,0.0,16.278000164031983,15.888499999046326,15.371499959627787,3.0839201225882134,2.451459640677446,3.363367535870962,61.83950100854177,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-03,16.479999542236328,16.68000030517578,15.819999694824219,16.139999389648438,46860,0.0,0.0,16.292000102996827,15.944999980926514,15.388999954859417,-0.9329776110204521,2.1762315615264702,3.612970483449307,50.00011453626913,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-04,16.139999389648438,16.280000686645508,13.800000190734863,14.34000015258789,308399,0.0,0.0,16.148000144958495,15.944999980926514,15.389333287874857,-11.196432847042503,1.2731274021624965,3.6107262261287376,31.64801256880338,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-05,14.15999984741211,14.899999618530273,13.819999694824219,14.239999771118164,108268,0.0,0.0,15.972000122070312,15.931499981880188,15.389333287874857,-10.843979074097604,0.25421423115329567,3.523003133816723,30.96796161596299,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-06,14.239999771118164,14.720000267028809,13.859999656677246,14.0,67417,0.0,0.0,15.764000129699706,15.90699999332428,15.387499952316285,-11.190054016659726,-0.8989744369434035,3.3761172550307332,29.33856171857269,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-07,14.0,14.779999732971191,13.819999694824219,13.899999618530273,57590,0.0,0.0,15.530000114440918,15.87299997806549,15.3839999516805,-10.495817668378201,-2.1609013047222,3.1786273265788223,28.661863549730512,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-10,13.84000015258789,14.0,13.260000228881836,13.380000114440918,115161,0.0,0.0,15.24000005722046,15.818999981880188,15.376333284378052,-12.204723988162353,-3.6601550371258686,2.878883341790418,25.383255777595878,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-11,13.579999923706055,14.260000228881836,12.239999771118164,13.5600004196167,86005,0.0,0.0,14.958000183105469,15.775499987602235,15.369833286603292,-9.346167578388993,-5.18208491102804,2.6393695587611297,28.43494999218227,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-12,13.680000305175781,13.680000305175781,13.119999885559082,13.5,53967,0.0,0.0,14.654000091552735,15.737999987602233,15.364333287874858,-7.874983515374452,-6.887786865570147,2.4320397945432686,28.023522626630495,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-13,13.5,14.899999618530273,13.5,14.520000457763672,57785,0.0,0.0,14.436000061035156,15.718499994277954,15.368333292007446,0.5818813824699649,-8.15917507211038,2.278494978063874,43.096812826698155,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-14,14.520000457763672,15.5600004196167,14.520000457763672,15.279999732971191,66213,0.0,0.0,14.285999965667724,15.712999987602235,15.380166625976562,6.9578592306611995,-9.081652281934911,2.1640426252829315,51.283223245345845,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-17,15.380000114440918,15.960000038146973,14.819999694824219,15.800000190734863,83108,0.0,0.0,14.252000045776366,15.713499999046325,15.394499961535136,10.861634437176784,-9.300919294610745,2.072168880497883,55.95253695170121,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-18,16.0,16.200000762939453,15.0,15.800000190734863,75476,0.0,0.0,14.398000049591065,15.721000003814698,15.408166631062825,9.737464483364953,-8.41549490428476,2.0303088631012205,55.95253695170121,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-19,15.979999542236328,15.979999542236328,14.819999694824219,15.0,108810,0.0,0.0,14.474000072479248,15.711500000953674,15.416333293914795,3.6341020097193764,-7.876395814526371,1.9146362589046295,47.78129365525244,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-20,15.0,15.699999809265137,14.600000381469727,15.34000015258789,65219,0.0,0.0,14.608000087738038,15.721500015258789,15.427666632334391,5.010953316356384,-7.0826570393411785,1.9045873230664745,51.052956404986745,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-21,15.34000015258789,15.699999809265137,14.859999656677246,15.399999618530273,34137,0.0,0.0,14.758000087738036,15.730999994277955,15.437666630744934,4.3501797464119445,-6.185238744478041,1.9001146387552643,51.62890181870168,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-24,15.399999618530273,16.0,14.920000076293945,15.619999885559082,53643,0.0,0.0,14.982000064849853,15.708999991416931,15.443666632970174,4.258442250351326,-4.627919835535654,1.7180722994907527,53.776618918103146,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-25,15.619999885559082,16.0,15.5,15.699999809265137,72777,0.0,0.0,15.196000003814698,15.677500009536743,15.452166628837585,3.316660998446423,-3.0712805321584784,1.4582639840204046,54.56660129255282,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-26,15.319999694824219,15.979999542236328,15.319999694824219,15.979999542236328,19141,0.0,0.0,15.44399995803833,15.655999994277954,15.464499958356221,3.470600787712515,-1.354113670906409,1.238320258898872,57.31621297449388,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-27,15.979999542236328,16.100000381469727,15.720000267028809,16.100000381469727,33941,0.0,0.0,15.601999950408935,15.640500020980834,15.479499959945679,3.191901247556016,-0.24615626431542326,1.0400856710601405,58.47607384667933,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-28,16.100000381469727,16.239999771118164,16.0,16.15999984741211,15456,0.0,0.0,15.689999961853028,15.630500030517577,15.493333292007446,2.9955378374874995,0.38066556552432984,0.8853274884423491,59.07487245166064,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-07-31,16.15999984741211,16.420000076293945,15.84000015258789,16.3799991607666,46824,0.0,0.0,15.7479998588562,15.629500007629394,15.511499953269958,4.013203629507171,0.7581806914422196,0.760726265770068,61.27972440465332,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-01,16.3799991607666,16.440000534057617,16.079999923706055,16.360000610351562,23273,0.0,0.0,15.803999900817871,15.629000043869018,15.53033328851064,3.518101196045426,1.1197124349455885,0.6353164064506716,60.95822249123814,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-02,16.3799991607666,16.3799991607666,16.1200008392334,16.3799991607666,19704,0.0,0.0,15.941999816894532,15.638500022888184,15.547999946276347,2.747455456673009,1.940721895080419,0.5820689279942503,61.17757072881741,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-03,16.299999237060547,16.3799991607666,15.119999885559082,15.279999732971191,61575,0.0,0.0,15.935999774932862,15.60550000667572,15.55799994468689,-4.116466184905139,2.1178415822354935,0.3053095652250128,45.9015419629386,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-04,15.279999732971191,15.960000038146973,15.0,15.720000267028809,33920,0.0,0.0,15.967999839782715,15.586500024795532,15.571499943733215,-1.553103552368781,2.4476297717914894,0.09633035427876911,51.15542065690351,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-07,16.040000915527344,16.540000915527344,15.479999542236328,16.239999771118164,79869,0.0,0.0,16.029999828338624,15.592500019073487,15.588666605949403,1.3100433251926262,2.805834912489767,0.024591026423141628,56.528620417338715,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-08,5.5,6.360000133514404,4.690000057220459,4.78000020980835,8890254,0.0,0.0,14.937999868392945,15.3075000166893,15.509333272775015,-68.00106940740929,-2.4138503863694294,-1.3013664258541133,15.65518421149288,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-09,4.855000019073486,5.110000133514404,4.400000095367432,4.605000019073486,3659197,0.0,0.0,13.80049991607666,15.019624996185303,15.424708271026612,-66.63164343989475,-8.116880950211991,-2.626197317470221,15.471218917289136,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-10,4.795000076293945,4.795000076293945,4.46999979019165,4.550000190734863,854634,0.0,0.0,12.645499897003173,14.720875000953674,15.337624939282735,-64.01881912305296,-14.098177613871798,-4.021156735613222,15.409929447713992,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-11,4.599999904632568,4.599999904632568,4.025000095367432,4.059999942779541,1004268,0.0,0.0,11.435499906539917,14.422374999523162,15.242291605472564,-64.49652419254848,-20.710008532450434,-5.379221361012543,14.845667567218015,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-14,4.059999942779541,4.110000133514404,3.815000057220459,4.099999904632568,692530,0.0,0.0,10.207499980926514,14.124874997138978,15.134791604677837,-59.833456651543194,-27.733873871492214,-6.672814756344021,15.118904247133386,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-15,4.110000133514404,4.264999866485596,3.9100000858306885,3.984999895095825,278097,0.0,0.0,8.96999990940094,13.830000001192094,15.02533326347669,-55.57413672970747,-35.14099849148402,-7.955452576816984,14.970179838357538,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-16,3.990000009536743,3.994999885559082,3.569999933242798,3.630000114440918,539783,0.0,0.0,7.695000004768372,13.520750004053117,14.915583270788193,-52.82650926326822,-43.08747663804419,-9.351516742002467,14.496124822286234,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-17,3.694999933242798,3.694999933242798,3.2049999237060547,3.4600000381469727,665561,0.0,0.0,6.51300003528595,13.205250006914138,14.79541661143303,-46.875479511723,-50.67870709092362,-10.747697386838736,14.263195439054698,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-18,3.4200000762939453,3.7799999713897705,3.180000066757202,3.2699999809265137,380936,0.0,0.0,5.26800000667572,12.881000012159348,14.674333284298578,-37.92710750222663,-59.10255413630263,-12.220884161450002,13.992575791815952,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-21,3.2699999809265137,3.9800000190734863,3.2699999809265137,3.744999885559082,890192,0.0,0.0,4.018500018119812,12.567624992132187,14.559708283344905,-6.806025415639935,-68.0249846678625,-13.6821648651539,18.172480223586973,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-22,3.8350000381469727,4.25,3.7300000190734863,4.014999866485596,715435,0.0,0.0,3.941999983787537,12.258500009775162,14.452999951442083,1.8518488837719234,-67.84272153490141,-15.183698533451938,20.53650998951639,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-23,4.21999979019165,4.21999979019165,4.025000095367432,4.150000095367432,115121,0.0,0.0,3.896499991416931,11.948749989271164,14.351249947150547,6.505841255200854,-67.38989438296377,-16.74070179759082,21.753739847202155,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-24,4.264999866485596,4.394999980926514,4.045000076293945,4.144999980926514,114803,0.0,0.0,3.855999970436096,11.63487496972084,14.249958286682764,7.494813607525338,-66.85826035543023,-18.351515592897126,21.74045661557173,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-25,4.184999942779541,4.184999942779541,3.9000000953674316,3.930000066757202,107799,0.0,0.0,3.842999982833862,11.313624954223632,14.145374957720438,2.2638585561269085,-66.03210731853734,-20.018910859278837,21.14263454580194,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-28,3.930000066757202,4.150000095367432,3.930000066757202,3.984999895095825,87294,0.0,0.0,3.831499981880188,11.009749966859818,14.037916630506516,4.006261619250019,-65.19902819397994,-21.5713395609291,21.735526668697887,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-29,3.990000009536743,3.994999885559082,3.8399999141693115,3.8949999809265137,73214,0.0,0.0,3.822499990463257,10.748624962568282,13.931541631619135,1.896664241834842,-64.43731171405662,-22.84683743704918,21.451307974745532,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-30,3.940000057220459,4.139999866485596,3.940000057220459,4.074999809265137,44141,0.0,0.0,3.866999959945679,10.494499963521957,13.827166626850763,5.378842810290068,-63.152127558368086,-24.10231071387505,23.60296793184972,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-08-31,4.170000076293945,4.465000152587891,3.940000057220459,4.184999942779541,502796,0.0,0.0,3.9394999504089356,10.249124962091447,13.725374962886175,6.231755183678109,-61.562572756405956,-25.327176927367102,24.955842004668455,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-01,4.184999942779541,4.199999809265137,4.0,4.019999980926514,77897,0.0,0.0,4.014499950408935,10.002124971151352,13.622041628758113,0.13700412468601586,-59.86352938012908,-26.57396560853691,24.261810153910048,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-04,4.199999809265137,4.199999809265137,3.9549999237060547,4.059999942779541,100623,0.0,0.0,4.045999956130982,9.769124966859817,13.522541628281276,0.3460204350063065,-58.583803873362406,-27.756739558275783,24.807744856393455,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-05,4.099999904632568,4.099999904632568,3.9049999713897705,3.9649999141693115,97758,0.0,0.0,4.040999960899353,9.529249954223634,13.42474996248881,-1.8807237680132847,-57.59372479144314,-29.017300278589257,24.358660400639565,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-06,3.9600000381469727,3.994999885559082,3.8299999237060547,3.9000000953674316,72187,0.0,0.0,4.015999960899353,9.289249956607819,13.320583299795787,-2.888442894953214,-56.767231157962215,-30.263940042698966,24.03802416794882,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-07,4.21999979019165,4.21999979019165,3.9000000953674316,3.9000000953674316,29878,0.0,0.0,3.991499972343445,9.023749947547913,13.219916637738546,-2.2923682227233733,-55.76672674282067,-31.741249246700598,24.03802416794882,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-08,3.9000000953674316,3.994999885559082,3.9000000953674316,3.9100000858306885,16381,0.0,0.0,3.9894999742507933,8.7394999563694,13.116999969879787,-1.9927281346839576,-54.35093547493845,-33.3727226009173,24.21601328604561,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-11,3.9800000190734863,4.175000190734863,3.809999942779541,3.9800000190734863,52991,0.0,0.0,3.9889999866485595,8.443999952077865,13.014333309729894,-0.2256196441513318,-52.759355645579284,-35.11769100177505,25.531398989035594,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-12,3.9000000953674316,3.9749999046325684,3.759999990463257,3.934999942779541,60832,0.0,0.0,3.9929999828338625,8.147374945878983,12.914291646083196,-1.4525429577677682,-50.99034953763165,-36.91194864450797,25.228245186709557,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-13,3.9200000762939453,5.239999771118164,3.765000104904175,5.090000152587891,856657,0.0,0.0,4.094500017166138,7.8996249496936795,12.821041641632716,24.31310614844624,-48.16842516903402,-38.38546687156935,43.70455257002284,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-14,5.090000152587891,5.090000152587891,4.420000076293945,4.420000076293945,336120,0.0,0.0,4.118000030517578,7.626624947786331,12.723541635274888,7.33365817237281,-46.00494899499614,-40.05894611416847,37.86018164739428,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-15,4.5,4.659999847412109,4.300000190734863,4.300000190734863,65487,0.0,0.0,4.146000051498413,7.349124962091446,12.626041636864345,3.714426852956559,-43.58511968588807,-41.7939115563016,36.90820845075419,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-18,4.400000095367432,4.585000038146973,4.050000190734863,4.105000019073486,121699,0.0,0.0,4.150500059127808,7.061249965429306,12.526249970992406,-1.0962544128690541,-41.221453999674864,-43.628380546601285,35.35259334992642,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-19,4.105000019073486,4.244999885559082,3.9700000286102295,4.230000019073486,84202,0.0,0.0,4.1770000696182255,6.774499970674515,12.430999972422917,1.268852012734226,-38.342311791281396,-45.50317765503058,37.180415548695755,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-20,4.5,4.5,4.070000171661377,4.099999904632568,23579,0.0,0.0,4.197000050544739,6.477499979734421,12.341166637341182,-2.3111780973074056,-35.20648299999196,-47.51306606512241,36.039177823439225,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-21,4.050000190734863,4.284999847412109,4.014999866485596,4.065000057220459,54490,0.0,0.0,4.213500046730042,6.176624971628189,12.250874974330266,-3.524385614397437,-31.783132923167546,-49.58217282789751,35.72127387796911,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-22,4.025000095367432,4.059999942779541,3.8949999809265137,3.994999885559082,82161,0.0,0.0,4.222000026702881,5.872499972581863,12.156166642904282,-5.3766020774062415,-28.105576050830265,-51.69118567480546,35.05524706559706,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-25,3.950000047683716,3.950000047683716,3.815000057220459,3.9000000953674316,60865,0.0,0.0,4.214000034332275,5.560499995946884,12.06533330877622,-7.45135112497924,-24.21544757838484,-53.913415786845896,34.12531824112074,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-26,3.8499999046325684,3.9000000953674316,3.75,3.7750000953674316,68310,0.0,0.0,4.198000049591064,5.245874983072281,11.975291643540064,-10.076225565191162,-19.975217420593623,-56.19417765159724,32.88902985214946,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-27,3.9200000762939453,4.079999923706055,3.859999895095825,3.940000057220459,24000,0.0,0.0,4.083000040054321,4.934875005483628,11.887458314498266,-3.502326265761179,-17.262341284889775,-58.48671032171006,36.17592696843966,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-28,3.940000057220459,3.940000057220459,3.8450000286102295,3.8450000286102295,11628,0.0,0.0,4.025500035285949,4.649000012874604,11.79783331155777,-4.483915168141294,-13.411485821939742,-60.594459252783295,35.10971280811175,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-09-29,4.050000190734863,4.105000019073486,3.8550000190734863,3.9200000762939453,76009,0.0,0.0,3.987500023841858,4.354000008106231,11.708999979496003,-1.692788643117756,-8.417546706064021,-62.814928552987816,36.69598788383918,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-02,3.9149999618530273,3.944999933242798,3.8450000286102295,3.8550000190734863,25521,0.0,0.0,3.9625000238418577,4.044375014305115,11.62079164981842,-2.712933857957289,-2.0244163850696855,-65.19707833873512,35.87741596349551,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-03,3.9000000953674316,4.099999904632568,3.799999952316284,3.805000066757202,24804,0.0,0.0,3.9200000286102297,4.020000010728836,11.533499985933304,-2.9336724748392116,-2.4875617376049743,-65.14501221977906,35.226465613433035,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-04,3.805000066757202,3.994999885559082,3.7300000190734863,3.75,110810,0.0,0.0,3.8850000381469725,3.998625010251999,11.444749989112218,-3.474904422687301,-2.8416010957192914,-65.06149095387818,34.48526029436891,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-05,3.75,3.7750000953674316,3.6500000953674316,3.700000047683716,22985,0.0,0.0,3.8485000371932983,3.9773750066757203,11.35724999109904,-3.8586459159263287,-3.240201622077759,-64.97941834693357,33.78921325145134,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-06,3.700000047683716,3.755000114440918,3.509999990463257,3.6649999618530273,82361,0.0,0.0,3.815500044822693,3.9675000071525575,11.268958322207133,-3.9444392924036573,-3.8311269579292024,-64.79266411577707,33.28279531286954,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-09,3.700000047683716,3.884999990463257,3.6050000190734863,3.625,9638,0.0,0.0,3.7880000352859495,3.9556250095367433,11.179499991734822,-4.303063193441732,-4.237635616284693,-64.61715629087885,32.67997501358609,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-10,3.625,3.8450000286102295,3.5799999237060547,3.8350000381469727,59732,0.0,0.0,3.794000029563904,3.951875013113022,11.093458326657613,1.0806538814861721,-3.9949386816450683,-64.37652806955019,38.93337844702345,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-11,3.819999933242798,3.819999933242798,3.625,3.7100000381469727,39302,0.0,0.0,3.771000027656555,3.9538750112056733,11.006041661898296,-1.6176077714719688,-4.625209017250984,-64.07541300798857,36.745364615076866,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-12,3.5999999046325684,3.875,3.494999885559082,3.5799999237060547,98027,0.0,0.0,3.744500017166138,3.9568750083446504,10.917374992370606,-4.393112370301919,-5.367240328052699,-63.75616839112117,34.569464152029596,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-13,3.5850000381469727,3.6649999618530273,3.390000104904175,3.565000057220459,146608,0.0,0.0,3.709000015258789,3.964250010251999,10.825249993801117,-3.8824469518985065,-6.438796602966633,-63.37959850791386,34.316957062025466,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-16,3.565000057220459,3.690000057220459,3.4049999713897705,3.559999942779541,23921,0.0,0.0,3.6795000076293944,3.9596250116825105,10.734083326657613,-3.247725631256193,-7.074533654743388,-63.11166132045054,34.2272080578703,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-17,3.5399999618530273,3.7300000190734863,3.444999933242798,3.5799999237060547,41559,0.0,0.0,3.6569999933242796,3.9487500131130218,10.639083329836527,-2.1055529056271736,-7.388414531684654,-62.884490226342685,34.95992497886317,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-18,3.5799999237060547,3.6549999713897705,3.4600000381469727,3.509999990463257,72094,0.0,0.0,3.6329999923706056,3.9327500104904174,10.547333325942358,-3.3856317689416993,-7.621893517773655,-62.71332393736553,33.551123686104404,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-19,3.505000114440918,3.694999933242798,3.505000114440918,3.680000066757202,33361,0.0,0.0,3.6309999942779543,3.9211250126361845,10.459499990940094,1.3494924967355122,-7.399024958992019,-62.51135316188516,39.88669823954232,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-20,3.559999942779541,3.559999942779541,3.299999952316284,3.5399999618530273,19578,0.0,0.0,3.618499994277954,3.9113750100135802,10.371166654427846,-2.1694081124516043,-7.487776420972973,-62.28606539319599,36.77686567897795,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-23,3.4800000190734863,3.5350000858306885,3.0199999809265137,3.2200000286102295,103185,0.0,0.0,3.577999997138977,3.8922500133514406,10.282333320379257,-10.005588843348507,-8.07373665963141,-62.14623770621085,30.855204461850775,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-24,3.2200000286102295,3.5,2.994999885559082,3.4200000762939453,70257,0.0,0.0,3.5365000009536742,3.880375015735626,10.191333319743475,-3.294215315377148,-8.861901578777209,-61.92475612373261,37.61612857734619,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-25,3.4200000762939453,3.634999990463257,2.619999885559082,3.200000047683716,238601,0.0,0.0,3.4855000019073485,3.8585000216960905,10.094833322366078,-8.191076002507542,-9.666969487919854,-61.77747667069241,33.71132084106999,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-26,3.200000047683716,3.200000047683716,2.8450000286102295,2.990000009536743,57210,0.0,0.0,3.4265000104904173,3.8286250233650208,9.994916659593581,-12.738946435642944,-10.503118232277846,-61.694277663734894,30.460832267493757,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-27,2.990000009536743,3.200000047683716,2.825000047683716,2.9549999237060547,120254,0.0,0.0,3.365499997138977,3.8020000219345094,9.892374990383784,-12.197298285006381,-11.480800165104556,-61.5663576680992,29.942632429443023,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-30,3.174999952316284,3.174999952316284,2.799999952316284,2.825000047683716,84666,0.0,0.0,3.2920000076293947,3.7711250245571137,9.786416657765706,-14.185903975193812,-12.705094999707367,-61.465721760736045,28.03491822449581,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-10-31,2.9000000953674316,3.1549999713897705,2.799999952316284,2.819999933242798,56398,0.0,0.0,3.2160000085830687,3.7425000250339506,9.682416655619939,-12.313435145628118,-14.068136618011264,-61.34745943966684,27.961127850849778,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-01,2.819999933242798,3.0,2.819999933242798,2.990000009536743,29968,0.0,0.0,3.1640000104904176,3.7197500228881837,9.582333322366079,-5.4993679006563765,-14.940520437614149,-61.181166447154034,34.293449131938104,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-02,3.0,3.0,2.8550000190734863,2.990000009536743,23067,0.0,0.0,3.0950000047683717,3.6970000207424163,9.47974998752276,-3.3925684998338688,-16.28347342700727,-61.00108098200474,34.293449131938104,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-03,2.994999885559082,3.0450000762939453,2.869999885559082,2.9700000286102295,9839,0.0,0.0,3.0380000114440917,3.6735000193119047,9.375333321094512,-2.238314107231978,-17.299578182303932,-60.81739290221794,33.88702516203345,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-06,2.880000114440918,2.9600000381469727,2.8450000286102295,2.950000047683716,49962,0.0,0.0,3.0110000133514405,3.6477500200271606,9.26841665705045,-2.0259038657335555,-17.45596609361348,-60.643223594697474,33.45997543608949,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-07,2.944999933242798,3.0999999046325684,2.8499999046325684,2.924999952316284,34584,0.0,0.0,2.9615000009536745,3.622500020265579,9.16362498998642,-1.2324851806731865,-18.24706737374826,-60.46870071370143,32.90181174397601,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-08,2.924999952316284,2.994999885559082,2.75,2.984999895095825,184622,0.0,0.0,2.939999985694885,3.5698750138282778,9.060333321491877,1.5306091707447456,-17.644175935950337,-60.59885561428262,35.6751852552771,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-09,2.9749999046325684,2.984999895095825,2.7899999618530273,2.880000114440918,92656,0.0,0.0,2.928999996185303,3.531375014781952,8.959833325942357,-1.6729218780540032,-17.057803718811304,-60.58659925562245,33.09703129274189,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-10,2.9000000953674316,2.944999933242798,2.7750000953674316,2.805000066757202,35617,0.0,0.0,2.9140000104904176,3.4940000116825103,8.858041656017303,-3.74056085589619,-16.599885496645946,-60.555615480663015,31.354044814938405,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-13,2.809999942779541,2.930000066757202,2.7750000953674316,2.930000066757202,29592,0.0,0.0,2.924500012397766,3.4646250128746034,8.74495832324028,0.18806819408855768,-15.589710241937413,-60.38145769469085,37.28231705752465,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-14,2.940000057220459,2.9800000190734863,2.684999942779541,2.8299999237060547,128713,0.0,0.0,2.925500011444092,3.4296250104904176,8.627208330233891,-3.2644022343003254,-14.699128840742812,-60.2464102035028,34.700506941815235,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-15,2.8299999237060547,2.9000000953674316,2.809999942779541,2.8499999046325684,17082,0.0,0.0,2.9115000009536742,3.3983750104904176,8.510624994834265,-2.1123165482040616,-14.326700497555823,-60.069031210361814,35.66016167888935,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-16,2.8499999046325684,2.9000000953674316,2.815000057220459,2.890000104904175,3946,0.0,0.0,2.9015000104904174,3.3690000116825103,8.395375001430512,-0.39634346181852503,-13.876521210180078,-59.87076204328625,37.634258986602596,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-17,2.9000000953674316,2.930000066757202,2.819999933242798,2.8949999809265137,8737,0.0,0.0,2.894000005722046,3.341500014066696,8.281500005722046,0.03455339331342207,-13.392189329965928,-59.65102926090794,37.89078204263529,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-20,2.8949999809265137,2.924999952316284,2.825000047683716,2.8949999809265137,27332,0.0,0.0,2.8884999990463256,3.316375011205673,8.168791671593985,0.22502966530497237,-12.90188868006797,-59.40189021176805,37.89078204263529,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-21,2.815000057220459,2.890000104904175,2.815000057220459,2.880000114440918,21822,0.0,0.0,2.8840000152587892,3.2940000116825106,8.05629167954127,-0.13869281541984838,-12.446872949897209,-59.11270169068564,37.35616824210549,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-22,2.869999885559082,2.880000114440918,2.7799999713897705,2.869999885559082,36375,0.0,0.0,2.872500014305115,3.267250007390976,7.946875011920929,-0.08703668350155595,-12.082025929845635,-58.88635466784306,36.98154144797354,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-23,2.869999885559082,2.950000047683716,2.8450000286102295,2.8450000286102295,105119,0.0,0.0,2.8690000057220457,3.242250007390976,7.832250008980433,-0.8365276076664251,-11.512067262489822,-58.60384942164229,36.00932326407093,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-24,2.9149999618530273,2.944999933242798,2.8350000381469727,2.9000000953674316,48727,0.0,0.0,2.8785000085830688,3.2167500078678133,7.719083346923193,0.7469198096319,-10.5152715771329,-58.327305674837646,39.76133709142483,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-27,2.940000057220459,2.940000057220459,2.75,2.8499999046325684,92160,0.0,0.0,2.8704999923706054,3.1916250050067902,7.60950001279513,-0.7141643543815864,-10.061489433515128,-58.05736251212069,37.60279283698239,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-28,2.8499999046325684,2.8499999046325684,2.7249999046325684,2.809999942779541,43926,0.0,0.0,2.868499994277954,3.1667500019073485,7.498083343108495,-2.0393952105667847,-9.418173441217556,-57.76587353062812,35.922669446373476,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-29,2.805000066757202,2.8499999046325684,2.7799999713897705,2.8299999237060547,42668,0.0,0.0,2.866499996185303,3.14375,7.3873333354791,-1.2733323749458192,-8.819085608419785,-57.44404838344669,37.428080977506596,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-11-30,2.8299999237060547,2.9200000762939453,2.690000057220459,2.690000057220459,96294,0.0,0.0,2.8464999914169313,3.1185000002384187,7.272250002622604,-5.497977680251802,-8.72214233768453,-57.117810868523655,31.796692391162892,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-01,2.690000057220459,2.825000047683716,2.6500000953674316,2.75,51142,0.0,0.0,2.83199999332428,3.0956250011920927,7.161833335955937,-2.8954799970894776,-8.516051129135267,-56.77608154254962,36.2253672839862,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-04,2.75,2.859999895095825,2.7049999237060547,2.7799999713897705,24925,0.0,0.0,2.8204999923706056,3.0745000004768372,7.051666669050852,-1.4359163655517382,-8.26150619830339,-56.400378169170295,38.37986336242157,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-05,2.7799999713897705,2.8499999046325684,2.630000114440918,2.7750000953674316,106278,0.0,0.0,2.8099999904632567,3.0480000019073485,6.9432916720708215,-1.2455478724060398,-7.8083993207073,-56.10151285783031,38.14855098788942,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-06,2.740000009536743,2.8450000286102295,2.7149999141693115,2.765000104904175,54127,0.0,0.0,2.799500012397766,3.024375003576279,6.833000006278356,-1.2323596121023812,-7.435420240962232,-55.738694558797064,37.65967684758074,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-07,2.765000104904175,2.8949999809265137,2.6500000953674316,2.805000066757202,85934,0.0,0.0,2.7955000162124635,3.0050000071525576,6.722375007470449,0.33983367875669,-6.971713492227563,-55.29853654678357,40.92102131706285,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-08,2.890000104904175,5.0,2.869999885559082,3.5799999237060547,1813365,0.0,0.0,2.8634999990463257,3.0053750038146974,6.6168750087420145,25.021823813457505,-4.720708882861238,-54.58014546377123,71.75385824347737,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-11,3.5899999141693115,3.7850000858306885,3.1500000953674316,3.609999895095825,312603,0.0,0.0,2.9394999980926513,3.0066250026226045,6.511291668812434,22.809998211880934,-2.2325698905384512,-53.8244459693975,72.35530367745886,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-12,3.5999999046325684,3.694999933242798,3.305000066757202,3.390000104904175,86406,0.0,0.0,2.997500014305115,3.0018750071525573,6.403041676680247,13.094248164334033,-0.14574200581363583,-53.11798425293205,61.93953865811323,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-13,3.5999999046325684,4.0,3.450000047683716,3.5999999046325684,155831,0.0,0.0,3.074500012397766,3.0041250050067902,6.2952083349227905,17.092206541413262,2.342612483624549,-52.27918052622106,66.84570134885897,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-14,3.6500000953674316,3.9000000953674316,3.484999895095825,3.75,120442,0.0,0.0,3.1805000066757203,3.0058750033378603,6.187291661898295,17.90598937679377,5.809456585651382,-51.41856619030561,69.83662400834848,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-15,3.75,4.050000190734863,3.75,3.9700000286102295,129460,0.0,0.0,3.302500009536743,3.01662500500679,6.080541656414668,20.211961155062028,9.476650364413116,-50.38887692144331,73.59854056330872,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-18,3.9549999237060547,3.9549999237060547,3.755000114440918,3.7750000953674316,71130,0.0,0.0,3.4020000219345095,3.0305000066757204,5.9774999956289925,10.964140829746963,12.258703660796314,-49.301547320924236,65.76882956408849,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-19,3.7750000953674316,3.950000047683716,3.75,3.805000066757202,42146,0.0,0.0,3.5050000190734862,3.0401250064373015,5.88970832824707,8.559202455097791,15.291312418135334,-48.38241833034673,66.36172929358635,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-20,3.805000066757202,3.9600000381469727,3.674999952316284,3.684999942779541,50246,0.0,0.0,3.597000002861023,3.0522500038146974,5.801749996344248,2.4464815081602356,17.847489503333534,-47.39087334445716,61.75416607876939,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-21,3.674999952316284,3.9749999046325684,3.5250000953674316,3.5950000286102295,102757,0.0,0.0,3.6759999990463257,3.0673750042915344,5.715041663249334,-2.203481242032378,19.841884148604912,-46.32803774614037,58.47496061000383,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-22,3.8499999046325684,3.8499999046325684,3.549999952316284,3.5899999141693115,42083,0.0,0.0,3.6769999980926515,3.0832500040531157,5.629124999046326,-2.3660615710761235,19.257277005076336,-45.226833574037286,58.28977073104581,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-27,3.5899999141693115,3.640000104904175,3.365000009536743,3.384999990463257,175200,0.0,0.0,3.6545000076293945,3.097250002622604,5.545833331346512,-7.374470286044883,17.991767036401242,-44.15176552248459,51.13892595644017,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-28,3.375,3.490000009536743,3.299999952316284,3.3350000381469727,74860,0.0,0.0,3.6490000009536745,3.1101250052452087,5.460624994834264,-8.60509626540524,17.32647384911076,-43.04452314181292,49.54251881911562,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2023-12-29,3.359999895095825,3.5,3.309999942779541,3.369999885559082,64827,0.0,0.0,3.625999999046326,3.119625002145767,5.376208327213923,-7.060124477511705,16.231918789991088,-41.97350972516294,50.702623319912064,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-02,3.369999885559082,4.465000152587891,3.365000009536743,4.199999809265137,329288,0.0,0.0,3.6709999799728394,3.1498749971389772,5.290208321809769,14.410237869198006,16.544306783831058,-40.4583939699862,68.9401908363898,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-03,4.164999961853027,4.175000190734863,3.815000057220459,4.09499979019165,158184,0.0,0.0,3.6834999561309814,3.1779999911785124,5.196999988953272,11.171435834436496,15.906229274878383,-38.849336195234564,65.63225963112205,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-04,4.09499979019165,4.09499979019165,3.859999895095825,3.9149999618530273,75493,0.0,0.0,3.697499942779541,3.2021249890327455,5.097958320379258,5.882353548056683,15.470194181784013,-37.18809005887426,60.29144983497729,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-05,3.9149999618530273,4.699999809265137,3.8499999046325684,4.5,346313,0.0,0.0,3.766999936103821,3.2414999902248383,5.003791652123133,19.458457030246606,16.211628797275814,-35.219125503567795,69.09388220878301,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-08,4.699999809265137,6.099999904632568,4.699999809265137,5.900000095367432,1743631,0.0,0.0,3.98849995136261,3.3143749952316286,4.927958319584529,47.92528938985662,20.33942921669518,-32.7434450478254,80.33104722731787,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-09,5.980000019073486,7.440000057220459,5.900000095367432,6.989999771118164,1911412,0.0,0.0,4.327999925613403,3.4171249866485596,4.858374983072281,61.5064669883856,26.656178586496754,-29.665268766724978,84.92634664086842,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-10,7.019999980926514,7.440000057220459,5.699999809265137,6.010000228881836,1546353,0.0,0.0,4.569999957084656,3.4972499907016754,4.780124988158544,31.509853070453865,30.67410019973288,-26.837687312253166,69.25907272619983,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-11,6.019999980926514,6.420000076293945,5.639999866485596,5.659999847412109,393972,0.0,0.0,4.797499942779541,3.565499985218048,4.6971249878406525,17.978111827404412,34.553357528233164,-24.091864822673827,64.67043171113438,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-12,5.659999847412109,6.5,5.659999847412109,6.309999942779541,332625,0.0,0.0,5.094999933242798,3.6524999856948854,4.618874988953272,23.84690923368542,39.49349632299802,-20.922302629311606,68.80409069065556,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-15,6.570000171661377,6.699999809265137,6.389999866485596,6.400000095367432,97654,0.0,0.0,5.397999954223633,3.741249990463257,4.539041660229365,18.56243330198233,44.283326909016054,-17.576213868144887,69.33902055829299,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-16,6.400000095367432,6.579999923706055,5.800000190734863,6.260000228881836,154849,0.0,0.0,5.603999996185303,3.8254999935626985,4.4570416589578,11.705928500054934,46.49065496315117,-14.169525746429212,67.40283740788418,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-17,6.260000228881836,6.260000228881836,5.960000038146973,6.099999904632568,76535,0.0,0.0,5.804500007629395,3.90562499165535,4.373208326101303,5.090875986127495,48.61897954952482,-10.691997718361659,65.16334283936135,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-18,6.110000133514404,6.400000095367432,6.110000133514404,6.139999866485596,50475,0.0,0.0,6.026999998092651,3.986749988794327,4.287874998648961,1.8748941169521367,51.175770114326546,-7.022709616057226,65.47220455692207,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-19,6.139999866485596,6.320000171661377,5.880000114440918,6.03000020980835,125867,0.0,0.0,6.1800000190734865,4.065499991178513,4.201791661977768,-2.427181372203702,52.01082357602023,-3.2436560820605567,63.797088495087486,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-22,6.03000020980835,6.550000190734863,5.900000095367432,6.239999771118164,135467,0.0,0.0,6.21399998664856,4.14974998831749,4.117291667064031,0.4184065742753105,49.74396057937015,0.7883415574637698,65.60625740593633,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-23,6.239999771118164,6.840000152587891,6.010000228881836,6.829999923706055,258909,0.0,0.0,6.1980000019073485,4.249374985694885,4.046875001986821,10.196836424721152,45.856744174668584,5.003860598823687,70.12359344060258,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-24,6.829999923706055,8.100000381469727,6.619999885559082,8.0,781793,0.0,0.0,6.396999979019165,4.3768749833106995,3.982541666428248,25.058621638867322,46.15450528999183,9.901549058647017,76.66803656745272,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-25,8.149999618530273,10.199999809265137,8.119999885559082,10.039999961853027,1840740,0.0,0.0,6.834999990463257,4.556624984741211,3.9308750013510387,46.8910018414286,50.00137192223741,15.918847156806107,83.4679124578552,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-26,10.279999732971191,10.899999618530273,8.420000076293945,8.6899995803833,1445662,0.0,0.0,7.072999954223633,4.703624975681305,3.963458329439163,22.861581176655864,50.373382036035544,18.674767960708618,69.11307359839196,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-29,8.640000343322754,9.369999885559082,7.71999979019165,9.279999732971191,351709,0.0,0.0,7.360999917984008,4.8648749709129335,4.0024166603883105,26.069825246143303,51.30912843588777,21.548438948406442,71.4259552285192,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-30,9.300000190734863,9.350000381469727,8.699999809265137,9.109999656677246,211819,0.0,0.0,7.64599986076355,5.025374960899353,4.040416655937831,19.147264224086673,52.147848076100644,24.377641932398713,69.80399329496186,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-01-31,9.109999656677246,9.109999656677246,8.260000228881836,8.319999694824219,119867,0.0,0.0,7.867999839782715,5.164624953269959,4.075916653871536,5.744787293411875,52.34406972380688,26.71075961193432,62.680696331469946,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-01,8.319999694824219,9.199999809265137,8.270000457763672,8.970000267028809,140043,0.0,0.0,8.150999879837036,5.319374960660935,4.116499990224838,10.047851788315167,53.232286502026746,29.220818007833806,65.77534409563722,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-02,8.979999542236328,8.979999542236328,8.430000305175781,8.619999885559082,155472,0.0,0.0,8.40999984741211,5.4654999554157255,4.1551249901453655,2.497027847290544,53.8743009059711,31.536354944271295,62.757592888890265,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-05,8.970000267028809,9.479999542236328,8.699999809265137,8.850000381469727,304799,0.0,0.0,8.670999908447266,5.617624962329865,4.198624992370606,2.0643579161854078,54.353485086534484,33.79677805323763,63.928779447722484,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-06,8.850000381469727,9.109999656677246,8.170000076293945,8.359999656677246,133354,0.0,0.0,8.823999881744385,5.756499952077865,4.239458322525024,-5.2583888404972665,53.287587165865865,35.783855250858785,59.62666934765877,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-07,8.329999923706055,8.550000190734863,7.760000228881836,7.880000114440918,91747,0.0,0.0,8.811999893188476,5.8639999568462375,4.277874990304311,-10.576484226559943,50.27285058043768,37.07740338688802,55.674205381278476,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-08,7.880000114440918,9.270000457763672,7.289999961853027,9.199999809265137,326497,0.0,0.0,8.727999877929687,6.00374995470047,4.323333323001862,5.4078819653628365,45.37580585108047,38.868542075118754,62.947939524681445,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-09,9.270000457763672,9.399999618530273,8.199999809265137,8.760000228881836,338001,0.0,0.0,8.734999942779542,6.137999957799911,4.362874992688497,0.28620819995493824,42.31019880799238,40.687046227229715,59.44616749636885,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-12,8.760000228881836,9.760000228881836,8.760000228881836,9.239999771118164,355500,0.0,0.0,8.730999946594238,6.278999954462051,4.405291656653087,5.829799881312276,39.05080442610483,42.533127062749614,61.933976880665945,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-13,9.239999771118164,9.739999771118164,8.5,8.600000381469727,200665,0.0,0.0,8.680000019073486,6.400249963998794,4.442416659990946,-0.9216548090779649,35.619703416244896,44.071356962987764,56.92009355280544,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-14,8.59000015258789,8.850000381469727,8.220000267028809,8.770000457763672,182859,0.0,0.0,8.725000095367431,6.520249974727631,4.482749996582667,0.5157634602220124,33.81388948560824,45.4520100317486,57.89515408635405,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-15,8.770000457763672,9.130000114440918,8.300000190734863,8.520000457763672,101401,0.0,0.0,8.680000114440919,6.638874983787536,4.520541667938232,-1.843313992715914,30.745045442758173,46.86016569371545,55.89169853997809,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-16,8.520000457763672,8.569999694824219,8.140000343322754,8.380000114440918,164486,0.0,0.0,8.656000137329102,6.75324998497963,4.557916669050853,-3.1885399550530305,28.175325311242883,48.16527978309741,54.749113938675336,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-19,8.380000114440918,8.380000114440918,7.800000190734863,8.199999809265137,121825,0.0,0.0,8.591000080108643,6.86612498164177,4.592291669050852,-4.551277699889874,25.12152200955764,49.514130992922745,53.242073710801414,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-20,8.199999809265137,8.579999923706055,7.869999885559082,8.369999885559082,111190,0.0,0.0,8.592000102996826,6.985499978065491,4.627166668574016,-2.5838013824081747,22.997639825005432,50.96711396864938,54.51549407322186,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-21,8.369999885559082,8.470000267028809,8.0,8.260000228881836,55624,0.0,0.0,8.630000114440918,7.1022499859333035,4.662500003973643,-4.28736825785143,21.51079068652148,52.32707731646904,53.50018394136702,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-22,8.260000228881836,8.260000228881836,7.059999942779541,7.420000076293945,272908,0.0,0.0,8.452000141143799,7.203124988079071,4.690500005086263,-12.210128343776793,17.3379631081173,53.56838248093335,46.39432833868096,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-23,7.5,7.960000038146973,7.429999828338623,7.630000114440918,154772,0.0,0.0,8.339000129699707,7.31049998998642,4.72104167342186,-8.502218542168567,14.068807073689605,54.849300126759815,48.24503592953968,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-26,7.639999866485596,8.0,7.320000171661377,7.449999809265137,63529,0.0,0.0,8.160000133514405,7.412499988079071,4.750625004371007,-8.700984223433835,10.084319010286382,56.03210064483931,46.75501018752899,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-27,7.449999809265137,7.449999809265137,7.0,7.21999979019165,169906,0.0,0.0,8.022000074386597,7.487999987602234,4.778291668494543,-9.997510306134862,7.131411427196825,56.70872577691385,44.84896633077706,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-28,7.21999979019165,7.960000038146973,6.840000152587891,7.699999809265137,158775,0.0,0.0,7.915000009536743,7.578124988079071,4.809874999523163,-2.716363866235674,4.445361114887924,57.553470492067774,49.477931594316736,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-02-29,7.699999809265137,8.350000381469727,7.699999809265137,8.050000190734863,127158,0.0,0.0,7.8679999828338625,7.681499993801117,4.843791667620341,2.3131699071947476,2.4279110744418313,58.584442125168565,52.601876458255646,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-01,8.050000190734863,8.119999885559082,7.380000114440918,7.739999771118164,148768,0.0,0.0,7.803999948501587,7.762499988079071,4.8754999995231625,-0.8200945387718906,0.5346210690659903,59.214439315726906,49.67223554981975,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-04,7.599999904632568,7.599999904632568,7.079999923706055,7.260000228881836,94432,0.0,0.0,7.709999990463257,7.7964999914169315,4.893583333492279,-5.836572790376654,-1.1094722125171712,59.320879202296176,45.451175780081336,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-05,7.25,8.0,6.909999847412109,7.869999885559082,262401,0.0,0.0,7.659999990463257,7.818499994277954,4.922333331902822,2.7415129942203116,-2.0272431275909297,58.83727222625056,51.13427915499374,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-06,7.869999885559082,8.760000228881836,7.489999771118164,8.600000381469727,310792,0.0,0.0,7.694000005722046,7.883249998092651,4.958166666825613,11.77541428481786,-2.4006595302241385,58.99526030131973,56.91878604058131,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-07,8.600000381469727,9.449999809265137,7.920000076293945,9.4399995803833,264206,0.0,0.0,7.895999956130981,7.977749991416931,5.002624996503195,19.55420001051868,-1.0247254598590154,59.471277519169064,62.42995967434885,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-08,9.4399995803833,9.930000305175781,8.75,9.350000381469727,388656,0.0,0.0,8.067999982833863,8.053750002384186,5.045291666189829,15.889940522602291,0.17693596703967754,59.6290271255284,61.52186710082748,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-11,9.329999923706055,9.5,8.550000190734863,9.050000190734863,159314,0.0,0.0,8.228000020980835,8.120000004768372,5.086541668574015,9.990279140228303,1.330049459963563,59.63695048319087,58.46885030032294,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-12,9.050000190734863,9.1899995803833,8.600000381469727,9.180000305175781,87650,0.0,0.0,8.424000072479249,8.193000006675721,5.12916667064031,8.974361659448986,2.819480844810291,59.73354996578676,59.40887160927993,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-13,9.180000305175781,9.180000305175781,8.710000038146973,8.890000343322754,84578,0.0,0.0,8.54300012588501,8.262750017642976,5.169958341121673,4.061807471901405,3.391729238372607,59.82237133172509,56.34508393618797,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-14,8.890000343322754,9.25,8.850000381469727,9.180000305175781,72421,0.0,0.0,8.656000137329102,8.33875002861023,5.213958342870076,6.053606279266596,3.8045283481383594,59.93127448003508,58.642032308614276,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-15,9.180000305175781,9.220000267028809,8.880000114440918,9.020000457763672,45479,0.0,0.0,8.784000205993653,8.413500034809113,5.257666679223378,2.6867058997674773,4.403639028367177,60.02345808753113,56.864309052505426,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-18,9.020000457763672,9.180000305175781,8.880000114440918,8.9399995803833,76019,0.0,0.0,8.952000141143799,8.481000030040741,5.299333341916403,-0.13405451933968282,5.553591668844681,60.038998923848595,55.95098945415365,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-19,8.949999809265137,9.119999885559082,8.670000076293945,8.960000038146973,127608,0.0,0.0,9.061000156402589,8.534250032901763,5.341958341995875,-1.1146685411350346,6.172189957759218,59.75882787796463,56.140649162796926,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-20,9.0,9.59000015258789,8.949999809265137,9.4399995803833,167131,0.0,0.0,9.145000076293945,8.570250022411347,5.387958337863286,3.225801001949316,6.706339399429617,59.06303436284679,60.532650411444465,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-21,9.510000228881836,9.899999618530273,9.510000228881836,9.850000381469727,144559,0.0,0.0,9.186000156402589,8.565500032901763,5.437916674216589,7.228393356866358,7.244178636592877,57.51436710154718,63.861533485005765,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-22,9.850000381469727,10.859999656677246,9.850000381469727,10.699999809265137,256062,0.0,0.0,9.321000099182129,8.61575003862381,5.495375005404155,14.79454667320525,8.185591009450501,56.78183982259768,69.58841552466842,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-25,10.819999694824219,11.15999984741211,9.920000076293945,10.119999885559082,279830,0.0,0.0,9.42800006866455,8.636750042438507,5.5484583377838135,7.339836782506,9.1614325103548,55.66035674493739,62.33003286775859,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-26,10.079999923706055,10.079999923706055,9.3100004196167,9.739999771118164,190134,0.0,0.0,9.48400001525879,8.65250004529953,5.598791668812434,2.6992804243725934,9.609938926391255,54.54227549664874,58.05735058678776,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-27,9.739999771118164,9.880000114440918,9.34000015258789,9.4399995803833,57239,0.0,0.0,9.538999938964844,8.680500042438506,5.64691666563352,-1.0378484035537867,9.889982055517276,53.72105799377248,54.86006069755427,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-03-28,9.4399995803833,9.4399995803833,9.050000190734863,9.210000038146973,63614,0.0,0.0,9.541999912261963,8.686500036716462,5.693458332618078,-3.479353145752526,9.848614193627334,52.56983592821105,52.474117665012926,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-02,9.199999809265137,9.199999809265137,8.5,8.970000267028809,204778,0.0,0.0,9.536999893188476,8.695250046253204,5.736250001192093,-5.945261953548203,9.680570914668332,51.58422391712668,50.02903014270363,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-03,8.960000038146973,9.0,8.619999885559082,9.0,59993,0.0,0.0,9.542999935150146,8.69900003671646,5.780333334207535,-5.6900339394333495,9.70226341960406,50.49305176288878,50.34051912139654,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-04,8.989999771118164,9.0,8.619999885559082,8.899999618530273,33613,0.0,0.0,9.536999893188476,8.712500035762787,5.8246666649977366,-6.679252194530916,9.463412958867245,49.57937572838209,49.23872449107945,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-05,8.850000381469727,9.149999618530273,8.640000343322754,9.050000190734863,43116,0.0,0.0,9.497999954223634,8.741750037670135,5.87037499944369,-4.716780013138985,8.651012821170248,48.91297469920667,50.97213677539874,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-08,9.0600004196167,9.65999984741211,9.0600004196167,9.4399995803833,123441,0.0,0.0,9.45699987411499,8.74775003194809,5.919374996423722,-0.17976413194443475,8.107797314470728,47.781649874069025,55.250819872416756,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-09,9.390000343322754,9.4399995803833,8.699999809265137,8.920000076293945,93651,0.0,0.0,9.27899990081787,8.751750028133392,5.963874997695287,-3.8689495458695116,6.024507909727544,46.746033937925716,49.09824623028901,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-10,8.930000305175781,11.15999984741211,8.84000015258789,11.0,482261,0.0,0.0,9.366999912261964,8.795750033855438,6.026291664441427,17.433544390241124,6.494612468609802,45.95626172153933,65.59978190384578,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-11,11.140000343322754,11.539999961853027,9.699999809265137,10.880000114440918,412932,0.0,0.0,9.480999946594238,8.852750027179718,6.086291664838791,14.755829297828738,7.096663946069488,45.4539235824513,64.3045851308157,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-12,10.5,11.979999542236328,10.34000015258789,11.520000457763672,371967,0.0,0.0,9.689000034332276,8.921500027179718,6.152791668971379,18.89772336612011,8.60281348219848,44.9992216081519,67.94020266498897,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-15,11.539999961853027,12.15999984741211,11.239999771118164,12.0,176072,0.0,0.0,9.968000030517578,9.008500015735626,6.2259583353996275,20.385232376217328,10.651051929909999,44.69258434504757,70.37710723004082,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-16,12.020000457763672,13.800000190734863,11.4399995803833,13.0600004196167,344981,0.0,0.0,10.377000045776366,9.12550002336502,6.306291671593984,25.85526030649257,13.714317234200784,44.704693321906745,74.91223581403291,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-17,13.260000228881836,14.300000190734863,13.199999809265137,13.899999618530273,502823,0.0,0.0,10.867000007629395,9.268000018596648,6.395458334684372,27.91018320393393,17.252913096938745,44.915337315758485,77.81126271179923,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-18,14.100000381469727,14.520000457763672,13.220000267028809,13.880000114440918,274963,0.0,0.0,11.36500005722046,9.405750024318696,6.486208335558573,22.129344870725433,20.8303434371113,45.01153120159068,77.5813976722888,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-19,13.899999618530273,13.979999542236328,13.180000305175781,13.180000305175781,103820,0.0,0.0,11.77800006866455,9.528750026226044,6.571416672070821,11.903550928321545,23.604880348921732,45.002980357708644,69.80819087118368,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-22,13.279999732971191,13.520000457763672,12.5,12.760000228881836,144180,0.0,0.0,12.110000133514404,9.662250030040742,6.6542083402474725,5.367465633369875,25.33312733435176,45.20510233500442,65.56354758710191,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-23,12.760000228881836,13.239999771118164,12.119999885559082,12.539999961853027,186740,0.0,0.0,12.472000122070312,9.785000026226044,6.735208340485891,0.545220005750185,27.460399475140445,45.281326598430574,63.3892985648519,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-24,12.520000457763672,12.520000457763672,9.420000076293945,9.649999618530273,458993,0.0,0.0,12.33700008392334,9.840000021457673,6.790708337227503,-21.78001497215328,25.376016839639874,44.903882375768895,43.147095593155065,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-25,9.729999542236328,11.260000228881836,9.720000267028809,10.600000381469727,279835,0.0,0.0,12.30900011062622,9.924500036239625,6.854125006993612,-13.884147483930345,24.026399976618656,44.79601737804831,48.92130303361336,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-26,10.600000381469727,11.420000076293945,10.600000381469727,11.15999984741211,118115,0.0,0.0,12.273000049591065,10.011000037193298,6.9223750054836275,-9.06868897320701,22.59514538002085,44.61799641399066,52.01510570740162,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-29,11.15999984741211,11.34000015258789,9.9399995803833,10.640000343322754,153180,0.0,0.0,12.13700008392334,10.075750041007996,6.98645834128062,-12.3341825018483,20.457534521262623,44.218279832483894,49.04451224791882,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-04-30,10.619999885559082,10.619999885559082,10.260000228881836,10.579999923706055,20332,0.0,0.0,11.889000034332275,10.146750044822692,7.0502500077088675,-11.01017837367462,17.170522401885258,43.92042883199967,48.69891595878778,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-02,10.5600004196167,17.979999542236328,10.34000015258789,12.34000015258789,3636586,0.0,0.0,11.733000087738038,10.273750042915344,7.128208343187968,5.17344294136858,14.203674789897924,44.12808307901656,58.03929581733382,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-03,12.399999618530273,13.680000305175781,11.15999984741211,11.760000228881836,1458962,0.0,0.0,11.521000099182128,10.371000051498413,7.202208344141642,2.0744738099314337,11.08861288181714,43.997501265487585,54.51666467834519,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-06,11.779999732971191,12.260000228881836,11.0,11.260000228881836,485470,0.0,0.0,11.329000091552734,10.437500047683717,7.272666678826014,-0.6090551868063502,8.541317746550417,43.51682138921543,51.60866463638898,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-07,11.279999732971191,11.579999923706055,9.59000015258789,9.979999542236328,469093,0.0,0.0,11.051000022888184,10.45100004673004,7.331416674455007,-9.691434969085714,5.741077155060142,42.550894469613986,44.99218344928166,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-08,9.979999542236328,10.760000228881836,9.479999542236328,10.5600004196167,207172,0.0,0.0,10.853000068664551,10.481250047683716,7.395833345254262,-2.6997111139234073,3.546809963406889,41.7183102754647,48.230936955822614,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-10,10.819999694824219,10.84000015258789,10.0,10.279999732971191,157383,0.0,0.0,10.916000080108642,10.512000036239623,7.457750010490417,-5.826313140986351,3.843227192506159,40.95404138584635,46.798419877255064,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-13,10.300000190734863,10.640000343322754,9.6899995803833,10.0,208330,0.0,0.0,10.85600004196167,10.53250002861023,7.517000009616216,-7.885040886633887,3.0714456441746254,40.115737862663266,45.34792974421683,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-14,9.949999809265137,10.0,9.5,9.649999618530273,126409,0.0,0.0,10.705000019073486,10.551500010490418,7.573291673262914,-9.85521157088725,1.4547695439554222,39.32515035360256,43.53164372786971,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-15,9.729999542236328,10.399999618530273,9.600000381469727,10.180000305175781,113101,0.0,0.0,10.659000015258789,10.576500010490417,7.634000009298324,-4.49385223189136,0.78003124555896,38.54466855656385,46.993795331783204,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-16,10.399999618530273,10.399999618530273,9.279999732971191,9.5,145382,0.0,0.0,10.551000022888184,10.588499999046325,7.689166675011317,-9.96114131938451,-0.35415758758576654,37.706730086335924,43.32364945041971,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-17,9.5,9.6899995803833,8.539999961853027,9.279999732971191,270973,0.0,0.0,10.244999980926513,10.597000002861023,7.7425833404064175,-9.419231329935556,-3.3216950253795905,36.86646351687541,42.176005852248956,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-20,9.619999885559082,10.0,8.649999618530273,9.100000381469727,324645,0.0,0.0,9.978999996185303,10.600500011444092,7.7947083433469135,-8.80849398789051,-5.862931131435591,35.996108443134126,41.214040100328546,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-21,9.069999694824219,10.0,8.6899995803833,9.989999771118164,296242,0.0,0.0,9.851999950408935,10.614250016212463,7.8537916739781695,1.4007290032873088,-7.181384126426725,35.148097337245034,47.58040169591674,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-22,9.979999542236328,9.979999542236328,9.109999656677246,9.229999542236328,189641,0.0,0.0,9.776999950408936,10.598749995231628,7.906958337624868,-5.594767423004113,-7.753273217996441,34.0433266835112,43.27094279405053,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-23,9.130000114440918,9.670000076293945,8.880000114440918,9.220000267028809,103145,0.0,0.0,9.642999935150147,10.56175000667572,7.960375006993612,-4.386598267821644,-8.69884319307749,32.679050891404756,43.2154836071137,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-24,9.220000267028809,9.539999961853027,9.020000457763672,9.170000076293945,162265,0.0,0.0,9.531999969482422,10.538000011444092,8.01320834159851,-3.7977328404055077,-9.546403879950377,31.50787502602142,42.91926167809779,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-27,9.300000190734863,9.300000190734863,8.800000190734863,9.0,91666,0.0,0.0,9.431999969482423,10.519500017166138,8.065791674455006,-4.580152363021354,-10.337944255041489,30.42117180489818,41.86844537449086,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-28,9.100000381469727,9.579999923706055,9.09000015258789,9.5,141109,0.0,0.0,9.417000007629394,10.521000027656555,8.122041674455007,0.8813846480127628,-10.493299278824031,29.53639551920324,46.05208972163332,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-29,9.800000190734863,9.800000190734863,9.289999961853027,9.4399995803833,102815,0.0,0.0,9.342999935150146,10.526750016212464,8.17754167119662,1.0382066349826584,-11.245161889844441,28.727561894185794,45.62772371280433,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-30,9.4399995803833,10.380000114440918,9.34000015258789,10.359999656677246,379136,0.0,0.0,9.428999900817871,10.561500000953675,8.240750000874202,9.873791130049964,-10.722909624897431,28.16187846777637,52.808527154195694,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-05-31,10.399999618530273,10.600000381469727,9.970000267028809,10.520000457763672,206234,0.0,0.0,9.55299997329712,10.599500012397765,8.305375003814698,10.122479714953904,-9.873107579382062,27.622172479019497,53.94763908518756,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-03,10.539999961853027,11.680000305175781,10.539999961853027,11.039999961853027,269240,0.0,0.0,9.746999931335449,10.653000020980835,8.374000002940496,13.26562059737722,-8.504647403182584,27.215190079293972,57.53518570751344,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-04,11.039999961853027,11.0600004196167,10.4399995803833,10.920000076293945,79663,0.0,0.0,9.839999961853028,10.699750018119811,8.435166670878727,10.975610961664437,-8.035234980357615,26.846930660650152,56.44245256213313,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-05,10.920000076293945,10.920000076293945,10.100000381469727,10.380000114440918,112293,0.0,0.0,9.955000019073486,10.723250031471252,8.491583339373271,4.269212401337462,-7.164339264150879,26.280925510679747,51.6853186578438,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-07,10.399999618530273,10.5,9.550000190734863,10.079999923706055,162821,0.0,0.0,10.04099998474121,10.752250027656554,8.547333337863286,0.38840692186147097,-6.614894939067561,25.79654498819941,49.20416396774043,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-10,10.039999961853027,10.119999885559082,9.649999618530273,10.079999923706055,58084,0.0,0.0,10.131999969482422,10.729250025749206,8.601333338022233,-0.5132258777436962,-5.566559217405123,24.73938172260465,49.20416396774043,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-11,10.039999961853027,10.039999961853027,9.399999618530273,9.430000305175781,58756,0.0,0.0,10.175,10.693000030517577,8.648666673898697,-7.321864322596751,-4.844290929011657,23.637555171233387,43.907675543519765,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-12,9.420000076293945,9.430000305175781,9.079999923706055,9.430000305175781,122386,0.0,0.0,10.168000030517579,10.64075002670288,8.69416667620341,-7.2580617931433205,-4.442825881624314,22.389533384808637,43.907675543519765,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-13,9.430000305175781,9.539999961853027,9.15999984741211,9.399999618530273,49473,0.0,0.0,10.164000034332275,10.575750017166138,8.741041672229766,-7.516729764082424,-3.8933407291731217,20.98958469406717,43.656128711969046,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-14,9.399999618530273,9.399999618530273,8.920000076293945,9.229999542236328,85224,0.0,0.0,10.051000022888184,10.479999995231628,8.786250001192093,-8.168346222090038,-4.093511188345782,19.27727977020609,42.181433255587834,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-17,9.229999542236328,9.25,8.770000457763672,9.0,74270,0.0,0.0,9.898999977111817,10.357500004768372,8.830541668335597,-9.08172521659217,-4.426744170364196,17.291785643321475,40.202753724247835,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-18,8.989999771118164,8.989999771118164,8.300000190734863,8.729999542236328,202291,0.0,0.0,9.667999935150146,10.228749990463257,8.873333330949148,-9.702114182929506,-5.482097576301353,15.275168969327169,37.952083017639175,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-19,8.720000267028809,8.850000381469727,8.359999656677246,8.739999771118164,63734,0.0,0.0,9.449999904632568,10.117749977111817,8.916249996423721,-7.513229001900291,-6.599788233449341,13.475395835356949,38.09032654078459,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-20,8.5,9.600000381469727,8.350000381469727,9.470000267028809,224430,0.0,0.0,9.358999919891357,10.035499978065491,8.966958332061768,1.186027867160623,-6.741069798742018,11.91643371624806,47.3177382274327,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-24,9.470000267028809,9.529999732971191,9.0,9.5,58673,0.0,0.0,9.300999927520753,9.959499979019165,9.018333331743877,2.139555682507055,-6.611778230690486,10.43614837303086,47.66296890784049,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-25,9.5,9.5,9.199999809265137,9.34000015258789,34623,0.0,0.0,9.226999950408935,9.951749992370605,9.068083333969117,1.224668936667196,-7.2826391591156465,9.744800812441422,45.934080884344596,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-26,9.34000015258789,9.34000015258789,8.949999809265137,9.100000381469727,38597,0.0,0.0,9.19399995803833,9.914249992370605,9.108916672070821,-1.0224013160498095,-7.264795974345368,8.841153666154899,43.39154643695105,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-27,9.100000381469727,9.100000381469727,8.699999809265137,8.699999809265137,91246,0.0,0.0,9.120999908447265,9.852749991416932,9.147291672229766,-4.6157230940461496,-7.426861369740623,7.712209738854884,39.47019673169008,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-06-28,8.699999809265137,8.979999542236328,8.239999771118164,8.239999771118164,130663,0.0,0.0,9.004999923706055,9.792749977111816,9.183333337306976,-8.49528216623295,-8.044216948731824,6.63611585707235,35.49729647072313,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-01,8.260000228881836,8.550000190734863,8.210000038146973,8.399999618530273,48819,0.0,0.0,8.92199993133545,9.738249969482421,9.215833334128062,-5.850709670730097,-8.381896549225209,5.668685797731894,37.840927716318454,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-02,8.40999984741211,9.15999984741211,8.279999732971191,8.699999809265137,95030,0.0,0.0,8.891999912261962,9.647249960899353,9.23916666507721,-2.1592454441217392,-7.8286563704521654,4.4168842344260595,42.08961219951854,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-03,8.699999809265137,9.0,8.510000228881836,8.800000190734863,52976,0.0,0.0,8.898999977111817,9.573249959945679,9.254250001907348,-1.1124821511583414,-7.043062550909178,3.447064407948604,43.47650774200678,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-04,8.800000190734863,9.699999809265137,8.800000190734863,9.199999809265137,84934,0.0,0.0,8.944999980926514,9.52174994945526,9.280833331743876,2.850752698517163,-6.057184567861314,2.59585113857568,48.762403918655096,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-05,9.199999809265137,9.5,9.010000228881836,9.229999542236328,54649,0.0,0.0,8.920999908447266,9.502999949455262,9.310583329200744,3.4637331796906685,-6.1243822382779,2.0666440914721447,49.146511507633576,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-08,9.229999542236328,9.529999732971191,9.229999542236328,9.4399995803833,67488,0.0,0.0,8.914999866485596,9.474999928474427,9.33666665951411,5.888948084804248,-5.910290936318734,1.4816130210598684,51.866684875085554,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-09,9.4399995803833,9.489999771118164,9.199999809265137,9.25,46767,0.0,0.0,8.905999851226806,9.449249935150146,9.36041665871938,3.862566298222067,-5.7491344567203235,0.9490312201862928,49.29736884982758,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-10,9.25,9.4399995803833,9.25,9.300000190734863,51509,0.0,0.0,8.92599983215332,9.431749939918518,9.385749991734823,4.190010817996166,-5.362208614381137,0.49010412832435574,49.999322803065326,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-11,6.079999923706055,6.690000057220459,5.820000171661377,5.889999866485596,1689036,0.0,0.0,8.644999837875366,9.337749946117402,9.383999991416932,-31.868132134827793,-7.4188119433427175,-0.4928606707356415,24.7911248016475,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-12,5.889999866485596,6.039999961853027,5.300000190734863,5.639999866485596,549033,0.0,0.0,8.384999847412109,9.224249935150146,9.379833324750264,-32.737030779716854,-9.09830168998317,-1.6587010047351765,23.84206869938876,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-15,5.639999866485596,5.730000019073486,5.380000114440918,5.400000095367432,179485,0.0,0.0,8.084999895095825,9.121749937534332,9.37458332379659,-33.20964544918612,-11.365692433339689,-2.697009323288665,22.934377523033774,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-16,5.409999847412109,5.630000114440918,5.150000095367432,5.25,233487,0.0,0.0,7.739999914169312,9.020999944210052,9.36633332570394,-32.17054188348204,-14.200199955249134,-3.6869644660861276,22.36137301863647,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-17,5.25,5.309999942779541,4.71999979019165,4.880000114440918,283501,0.0,0.0,7.347999906539917,8.915499937534332,9.350083327293396,-33.58736831096599,-17.581740137703623,-4.6479092703964655,20.969637413974255,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-18,4.880000114440918,4.880000114440918,4.380000114440918,4.534999847412109,435410,0.0,0.0,6.881499910354615,8.779124939441681,9.32120832602183,-34.09867170690098,-21.615195616611743,-5.815591365626125,19.73618071078154,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-19,4.539999961853027,4.735000133514404,4.445000171661377,4.65500020980835,135260,0.0,0.0,6.423999977111817,8.664749956130981,9.276333328088125,-27.537356376187226,-25.860526736073446,-6.592943033917395,21.466537041964514,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-22,4.65500020980835,4.65500020980835,4.28000020980835,4.46999979019165,84270,0.0,0.0,5.9269999980926515,8.545999944210052,9.24116666316986,-24.582422952081554,-30.64591578767542,-7.522499531691759,20.724748974274448,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-23,4.46999979019165,4.829999923706055,4.440000057220459,4.579999923706055,98531,0.0,0.0,5.459999990463257,8.431249940395356,9.201999998092651,-16.117217368026736,-35.240918854705086,-8.375897172973842,22.44090112765916,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-24,4.579999923706055,5.679999828338623,4.579999923706055,5.059999942779541,543282,0.0,0.0,5.035999965667725,8.332749938964843,9.168250000476837,0.4765682540792882,-39.563769433199454,-9.112972066299887,29.60247206713605,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-25,5.059999942779541,5.139999866485596,4.664999961853027,4.934999942779541,128221,0.0,0.0,4.940499973297119,8.218624937534333,9.140041669209799,-0.1113253830038536,-39.88653806631408,-10.081099901102823,28.855243060609766,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-26,4.934999942779541,4.934999942779541,4.514999866485596,4.644999980926514,262176,0.0,0.0,4.840999984741211,8.098749947547912,9.104000000158946,-4.048750349772524,-40.22534321846869,-11.041850314076047,27.143404992311687,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-29,4.639999866485596,4.639999866485596,4.300000190734863,4.519999980926514,146076,0.0,0.0,4.752999973297119,7.952749955654144,9.069833334287008,-4.9021669194114335,-40.23451007763808,-12.316470848586759,26.41595847010298,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-30,4.514999866485596,4.59499979019165,4.349999904632568,4.485000133514404,97709,0.0,0.0,4.67649998664856,7.801874947547913,9.033458332220713,-4.094939670285235,-40.05928038979452,-13.633575751160157,26.20419628456814,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-07-31,4.480000019073486,4.485000133514404,4.304999828338623,4.440000057220459,49363,0.0,0.0,4.6324999809265135,7.636874949932098,9.000791668891907,-4.155422007525923,-39.34037140456644,-15.153297277990674,25.91652888071762,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-01,4.385000228881836,4.46999979019165,4.304999828338623,4.364999771118164,34915,0.0,0.0,4.615499973297119,7.472999942302704,8.971499999364218,-5.42736872772655,-38.23765544048813,-16.702893130108766,25.41573746124007,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-02,4.360000133514404,4.360000133514404,4.005000114440918,4.195000171661377,101566,0.0,0.0,4.569499969482422,7.3183749437332155,8.929791669050852,-8.195640667953954,-37.561275493334456,-18.045401113919983,24.270920754246077,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-05,4.195000171661377,4.195000171661377,3.8399999141693115,3.9749999046325684,136970,0.0,0.0,4.519999980926514,7.165749943256378,8.889916666348775,-12.057523862693262,-36.922164229575934,-19.394633131027298,22.837288465072945,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-06,2.7533280849456787,2.888227939605713,2.7533280849456787,2.770622968673706,49250,0.0,0.0,4.339062285423279,6.98301551938057,8.83600519299507,-36.146964795103656,-37.86262863972302,-20.970898422326613,16.938625389468044,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-07,2.770622968673706,2.874392032623291,2.732574939727783,2.7879180908203125,73483,0.0,0.0,4.111854100227356,6.816963464021683,8.787571173906326,-32.19802982148223,-39.68202819438966,-22.424941669162628,17.269088320042158,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-08,2.7879180908203125,2.7879180908203125,2.6218879222869873,2.6288061141967773,302611,0.0,0.0,3.8812347173690798,6.646933609247208,8.736394554376602,-32.26881892938619,-41.608643240102325,-23.91674199378568,16.614200368702413,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-09,2.0753729343414307,2.490447998046875,1.8885890245437622,2.3520889282226562,753806,0.0,0.0,3.6519436120986937,6.470735841989518,8.684995291630427,-35.59350367759481,-43.562158906244996,-25.49522913126679,15.512419859023453,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-12,2.3555479049682617,2.4178099632263184,2.2725329399108887,2.359006881713867,243908,0.0,0.0,3.435844302177429,6.298961025476456,8.634820348024368,-31.341275266202484,-45.453793279860136,-27.05162618794209,15.66299732792065,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-13,2.379760980606079,2.407433032989502,2.234484910964966,2.275991916656494,248762,0.0,0.0,3.2149434804916384,6.130860823392868,8.585453615585964,-29.20584979277947,-47.561303818466676,-28.5901351529877,15.31036978083199,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-14,2.275991916656494,2.414350986480713,2.220649003982544,2.227566957473755,581145,0.0,0.0,2.9937001705169677,5.968300008773804,8.534266674518586,-25.59151449394857,-49.83998515295769,-30.066633298513917,15.096856232107015,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-15,2.509999990463257,3.2799999713897705,2.4000000953674316,2.549999952316284,2993665,0.0,0.0,2.81220018863678,5.8135500133037565,8.486683338880539,-9.323668968516701,-51.626799766040946,-31.497974165363285,22.815237505798706,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-16,2.75,2.8350000381469727,2.4000000953674316,2.4649999141693115,274196,0.0,0.0,2.6392001628875734,5.6384250044822695,8.445391670862834,-6.600494012082349,-53.192599692475476,-33.236666525068195,22.241219675052363,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-19,2.4749999046325684,2.7899999618530273,2.4649999141693115,2.5899999141693115,577503,0.0,0.0,2.5007001638412474,5.465675002336502,8.403391669193903,3.570989901919852,-54.24718515513213,-34.95870218243918,25.220811095029504,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-20,2.630000114440918,2.630000114440918,2.2300000190734863,2.325000047683716,606812,0.0,0.0,2.4561378717422486,5.2902999997138975,8.360683337847393,-5.339188225842992,-53.57280547653105,-36.724071634604215,23.191896076703472,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-21,2.325000047683716,2.4000000953674316,2.2049999237060547,2.240000009536743,271742,0.0,0.0,2.4013460636138917,5.118799990415573,8.319183339675268,-6.7189838450161465,-53.08771454031872,-38.469922089547545,22.564855685922822,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-22,2.2699999809265137,2.299999952316284,2.200000047683716,2.255000114440918,129369,0.0,0.0,2.363965463638306,4.9576749980449675,8.273808342218398,-4.609430673732547,-52.31705457557175,-40.07989074695317,22.96070638081278,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-23,2.315000057220459,2.319999933242798,2.200000047683716,2.255000114440918,228247,0.0,0.0,2.354256582260132,4.8080500066280365,8.22551667491595,-4.2160429142318,-51.03510614459664,-41.547136834694136,22.96070638081278,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-26,2.255000114440918,2.255000114440918,2.005000114440918,2.1449999809265137,360925,0.0,0.0,2.3328558921813967,4.6516750156879425,8.178891676664353,-8.052615332326573,-49.84912135276528,-43.12585128178317,22.004032620264113,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-27,2.1449999809265137,2.1500000953674316,2.015000104904175,2.109999895095825,280734,0.0,0.0,2.3162566900253294,4.48692501783371,8.135975007216135,-8.904746862371661,-48.37763767348135,-44.8508013624173,21.694301481613792,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-28,2.125,2.2799999713897705,2.0999999046325684,2.25,308433,0.0,0.0,2.3184999942779543,4.323175013065338,8.089141674836476,-2.95449620215708,-46.37043406128436,-46.55582524269818,26.17095784215674,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-29,2.244999885559082,2.25,2.049999952316284,2.174999952316284,430757,0.0,0.0,2.280999994277954,4.147550016641617,8.035600004593531,-4.647086463287086,-45.00367722810631,-48.385310191265376,25.33534505835837,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-08-30,2.180000066757202,2.2699999809265137,2.174999952316284,2.200000047683716,193129,0.0,0.0,2.2545000076293946,3.9718000292778015,7.975266675154368,-2.4173856625081798,-43.23732335438514,-50.19853014255572,26.181433715589336,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-02,2.200000047683716,2.424999952316284,2.180000066757202,2.244999885559082,155407,0.0,0.0,2.2200000047683717,3.791925036907196,7.916058337688446,1.1261207539194926,-41.4545387063066,-52.0983186941183,27.768093647463346,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-03,2.244999885559082,2.384999990463257,2.115000009536743,2.200000047683716,171130,0.0,0.0,2.2075000047683715,3.615675038099289,7.85897500316302,-0.3397489045732812,-38.94639364690185,-53.993045700691496,27.13987506847799,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-04,2.200000047683716,3.1700000762939453,2.200000047683716,2.674999952316284,1883894,0.0,0.0,2.250999999046326,3.4500500321388246,7.804766666889191,18.83607078852035,-34.75456940979953,-55.79560313090129,42.04465213028264,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-05,2.700000047683716,3.0899999141693115,2.619999885559082,2.7699999809265137,969429,0.0,0.0,2.3024999856948853,3.3720500349998472,7.753766663869222,20.304017291471936,-31.718095467258106,-56.51081363187226,44.49043713078561,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-06,2.7699999809265137,2.7699999809265137,2.2200000286102295,2.315000057220459,920106,0.0,0.0,2.308499979972839,3.288925039768219,7.696558328469594,0.2815714664938521,-29.80989374766879,-57.26758767483806,36.53737501941169,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-09,2.309999942779541,2.450000047683716,2.119999885559082,2.259999990463257,632750,0.0,0.0,2.3199999809265135,3.2104250371456144,7.640224991242091,-2.586206506747259,-27.73542586780898,-57.97996733308651,35.70647035099725,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-10,2.2750000953674316,2.3550000190734863,2.115000009536743,2.1700000762939453,390922,0.0,0.0,2.3259999990463256,3.1334250390529634,7.583808328708013,-6.706789459000053,-25.768130079495105,-58.68269735679385,34.33065695899258,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-11,2.1700000762939453,2.2699999809265137,2.134999990463257,2.1649999618530273,343621,0.0,0.0,2.3174999952316284,3.065550035238266,7.52718332807223,-6.580368228365803,-24.40182125256019,-59.273610039422586,34.251695127469034,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-12,2.2200000286102295,2.234999895095825,2.0850000381469727,2.0950000286102295,192111,0.0,0.0,2.309500002861023,3.004550039768219,7.465974998474121,-9.287723489286403,-23.13324882952572,-59.75676264141948,33.10376653279462,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-13,2.0950000286102295,2.140000104904175,2.0,2.0450000762939453,443481,0.0,0.0,2.294000005722046,2.939300036430359,7.400933329264323,-10.854399686443198,-21.954207556571852,-60.284738347689796,32.2717873284918,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-16,2.059999942779541,2.234999895095825,2.0450000762939453,2.2249999046325684,335274,0.0,0.0,2.2920000076293947,2.8831750392913817,7.330308330059052,-2.9232156533072726,-20.50430596843972,-60.667752167143085,38.28508092485687,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-17,2.2750000953674316,2.390000104904175,2.0999999046325684,2.3399999141693115,257942,0.0,0.0,2.305999994277954,2.827175039052963,7.265474996964136,1.4744111004216784,-18.43448097750574,-61.08754017824998,41.8380561206095,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-18,2.384999990463257,2.984999895095825,2.265000104904175,2.7249999046325684,466605,0.0,0.0,2.3109999895095825,2.7688000380992888,7.207016664743423,17.914319212560482,-16.53424018673354,-61.58188378217299,51.83526397800801,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-19,2.7300000190734863,2.9800000190734863,2.5250000953674316,2.5399999618530273,890760,0.0,0.0,2.287999987602234,2.708925038576126,7.149516667922338,11.013984948264053,-15.538453260232707,-62.110375226758585,47.60123713071253,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-20,2.5450000762939453,2.6700000762939453,2.3499999046325684,2.5,272958,0.0,0.0,2.306499981880188,2.655300039052963,7.09360000093778,8.389335340990414,-13.13599412656876,-62.56766608348469,46.71277960636348,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-23,2.450000047683716,2.494999885559082,2.359999895095825,2.4049999713897705,115416,0.0,0.0,2.3209999799728394,2.6024250388145447,7.038891665140787,3.6191293469082293,-10.813954471092083,-63.02791458344611,44.584394809923104,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-24,2.200000047683716,2.434999942779541,2.174999952316284,2.4100000858306885,2763255,0.0,0.0,2.344999980926514,2.5505500376224517,6.9839749991893765,2.7718595067319773,-8.059048192112538,-63.479966094974685,44.72714189591458,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-25,2.4049999713897705,2.5199999809265137,2.369999885559082,2.4600000381469727,925800,0.0,0.0,2.3744999885559084,2.501050037145615,6.930308336019516,3.6007601601658696,-5.059876720184887,-63.91141756064904,46.219036283674164,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-26,2.4600000381469727,2.4600000381469727,2.319999933242798,2.375,999875,0.0,0.0,2.4024999856948854,2.4513000428676603,6.874683334430059,-1.1446404103487013,-1.9907826997663667,-64.34308427573728,44.042660343786146,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-27,2.369999885559082,2.390000104904175,2.255000114440918,2.299999952316284,511735,0.0,0.0,2.427999973297119,2.4039250373840333,6.815183337529501,-5.271829587667436,1.0014844697189207,-64.72692049022038,42.15639162349843,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-09-30,2.2950000762939453,2.2950000762939453,2.140000104904175,2.2200000286102295,709174,0.0,0.0,2.4274999856948853,2.3600500404834746,6.759350003798803,-8.547887056949161,2.8579879262896113,-65.08465992799441,40.17965443483101,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-01,2.2200000286102295,2.434999942779541,2.174999952316284,2.2950000762939453,1079758,0.0,0.0,2.4230000019073485,2.348159468173981,6.686808337767919,-5.282704313357145,3.187199794039824,-64.8837031127199,42.88362992906105,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-02,2.3299999237060547,2.359999895095825,2.240000009536743,2.25,272155,0.0,0.0,2.3755000114440916,2.334711515903473,6.6148916701475775,-5.2830987513992405,1.7470464878756005,-64.70521918839852,41.66666253342267,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-03,2.2100000381469727,2.315000057220459,2.2100000381469727,2.255000114440918,460573,0.0,0.0,2.3470000267028808,2.3253663659095762,6.537683333953222,-3.91989395889383,0.9303334352151619,-64.43133986265639,41.8640789835529,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-04,2.255000114440918,2.325000047683716,2.200000047683716,2.2200000286102295,630011,0.0,0.0,2.3190000295639037,2.322064143419266,6.45618333419164,-4.269081487346575,-0.1319564691632619,-64.0334850604114,40.822622184741974,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-07,2.25,2.259999990463257,2.174999952316284,2.2200000286102295,418248,0.0,0.0,2.3005000352859497,2.318588972091675,6.36584999759992,-3.4992395323182053,-0.7801700527112607,-63.577700181973505,40.822622184741974,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-08,2.2200000286102295,2.259999990463257,2.1600000858306885,2.200000047683716,201548,0.0,0.0,2.2795000314712524,2.3166891753673555,6.268350001176199,-3.4876061719650444,-1.6052711900898884,-63.04148340579818,40.16051420506412,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-09,2.200000047683716,2.200000047683716,2.119999885559082,2.174999952316284,608043,0.0,0.0,2.2510000228881837,2.3153750002384186,6.170808333158493,-3.376280310934263,-2.7803261823076646,-62.47857857135376,39.30240256833498,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-10,2.174999952316284,2.2750000953674316,2.134999990463257,2.25,488268,0.0,0.0,2.2385000228881835,2.3078750014305114,6.079724997282028,0.5137358496418,-3.0060110924259997,-62.03981261550056,43.221896245992774,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-11,2.240000009536743,2.2750000953674316,2.194999933242798,2.2300000190734863,169267,0.0,0.0,2.231500029563904,2.3020000040531157,5.991974995533625,-0.06721982839097805,-3.0625531870149016,-61.58194909409652,42.434968111106066,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-14,2.255000114440918,2.2750000953674316,2.190000057220459,2.2200000286102295,256731,0.0,0.0,2.231500029563904,2.292750006914139,5.9059749960899355,-0.5153484562544116,-2.671463402705327,-61.17914470630066,42.022991172482556,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-15,2.2200000286102295,2.234999895095825,2.1549999713897705,2.184999942779541,278464,0.0,0.0,2.2205000162124633,2.2892500042915342,5.843766665458679,-1.5987423181142428,-3.0031664497188615,-60.82578009449235,40.539511024669565,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-16,2.180000066757202,2.2200000286102295,2.1449999809265137,2.180000066757202,499388,0.0,0.0,2.2135000228881836,2.287750005722046,5.773599996169408,-1.5134382554589076,-3.2455461762933306,-60.3756753630336,40.32053534839885,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-17,2.2300000190734863,2.2300000190734863,2.140000104904175,2.1649999618530273,267990,0.0,0.0,2.2045000076293944,2.285500001907349,5.698641663789749,-1.7917915917289255,-3.544082004391006,-59.893951282638994,39.62894390251181,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-18,2.1649999618530273,2.234999895095825,2.1449999809265137,2.2049999237060547,528685,0.0,0.0,2.202999997138977,2.284249997138977,5.628349993626276,0.09078195958579696,-3.556966185915109,-59.415281570518275,42.46307499864849,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-21,2.2100000381469727,2.244999885559082,2.1449999809265137,2.2049999237060547,437805,0.0,0.0,2.2014999866485594,2.2857499957084655,5.55855832695961,0.15897965381427975,-3.6858803114114367,-58.87872607862491,42.46307499864849,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-22,2.2049999237060547,2.2200000286102295,2.130000114440918,2.1500000953674316,457543,0.0,0.0,2.196499991416931,2.286750000715256,5.473641659816106,-2.1169996007831946,-3.9466495799757864,-58.22251176025867,39.50560085066543,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-23,2.174999952316284,2.174999952316284,2.1050000190734863,2.1500000953674316,391558,0.0,0.0,2.194000005722046,2.2842500030994417,5.393558325370153,-2.005465371005497,-3.9509684690790343,-57.64855286064462,39.50560085066543,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-24,2.119999885559082,2.1649999618530273,2.075000047683716,2.0850000381469727,793969,0.0,0.0,2.177500009536743,2.2820000052452087,5.317099990447362,-4.247989482647562,-4.579316190546489,-57.08186775977464,36.062953195702704,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-25,2.0850000381469727,2.119999885559082,2.049999952316284,2.0799999237060547,690612,0.0,0.0,2.1625,2.279000002145767,5.251266660292943,-3.8150324297778218,-5.111891269683092,-56.60094697954965,35.8044760694236,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-28,2.0850000381469727,2.200000047683716,2.049999952316284,2.1600000858306885,1308028,0.0,0.0,2.156500005722046,2.276875007152557,5.181266657511393,0.16230373750779378,-5.28685154223953,-56.05562968175508,42.86097470840251,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-29,2.1700000762939453,2.255000114440918,2.1500000953674316,2.180000066757202,907205,0.0,0.0,2.156000018119812,2.2763750076293947,5.113766660292943,1.113174788297076,-5.288012260991241,-55.48535631661004,44.503358365537366,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-30,2.180000066757202,2.2300000190734863,2.1500000953674316,2.190000057220459,433823,0.0,0.0,2.157000017166138,2.264250010251999,5.048683327436447,1.5299044873294203,-4.736667443977384,-55.151672953080435,45.349207557046114,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-10-31,2.194999933242798,2.2300000190734863,2.1500000953674316,2.190000057220459,537918,0.0,0.0,2.1595000267028808,2.2497500121593474,4.986516664425532,1.4123653688555673,-4.011556171516285,-54.88333513032533,45.349207557046114,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-01,2.2200000286102295,2.2200000286102295,2.1500000953674316,2.174999952316284,225317,0.0,0.0,2.1565000295639036,2.2462500095367433,4.919808328151703,0.857867957280839,-3.9955472272362624,-54.34273329951809,44.17783579677965,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-04,2.1600000858306885,2.174999952316284,2.059999942779541,2.109999895095825,685582,0.0,0.0,2.147000026702881,2.2425000071525574,4.858224993944168,-1.7233409942652143,-4.258639025421393,-53.84116606481052,39.425507196681835,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-05,2.0999999046325684,2.1649999618530273,2.049999952316284,2.140000104904175,527711,0.0,0.0,2.146000027656555,2.241750007867813,4.798724997043609,-0.27958633154969353,-4.2712157856677475,-53.28446599359399,42.49994372738305,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-06,2.1500000953674316,2.174999952316284,2.0799999237060547,2.0850000381469727,400433,0.0,0.0,2.1395000219345093,2.239750009775162,4.740266660849254,-2.547323357270098,-4.475945413689998,-52.750548228147686,38.62903272110388,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-07,2.299999952316284,2.450000047683716,2.1649999618530273,2.3550000190734863,2659403,0.0,0.0,2.1665000200271605,2.2462500095367433,4.676641662915547,8.700669157804242,-3.550361231875079,-51.96873800811224,58.575540868036065,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-08,2.369999885559082,2.8399999141693115,2.369999885559082,2.7049999237060547,3238200,0.0,0.0,2.2290000200271605,2.262750005722046,4.622266666094462,21.35486314051689,-1.4915472592879682,-51.04674461298586,71.50461274269888,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-11,2.680000066757202,2.799999952316284,2.565000057220459,2.6500000953674316,1007451,0.0,0.0,2.278000020980835,2.2733750104904176,4.567516664663951,16.33011725023713,0.20344247953264805,-50.227329698036726,67.91730182964226,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-12,2.6500000953674316,2.805000066757202,2.494999885559082,2.549999952316284,972865,0.0,0.0,2.3150000095367433,2.278625011444092,4.5123499969641365,10.151185391423255,1.5963573606873858,-49.50247624902484,61.84232355625065,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-13,2.569999933242798,2.674999952316284,2.4649999141693115,2.5899999141693115,677923,0.0,0.0,2.3549999952316285,2.2752500116825103,4.458933329582214,9.978765155562956,3.5051085876116272,-48.97322199038816,63.258021128107366,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-14,2.615000009536743,2.7249999046325684,2.5350000858306885,2.549999952316284,697465,0.0,0.0,2.390999984741211,2.275500011444092,4.401016662518184,6.649935951056996,5.0758063158092375,-48.29603734919533,60.82764090309701,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-15,2.5950000286102295,2.680000066757202,2.555000066757202,2.625,470860,0.0,0.0,2.4359999895095825,2.278625011444092,4.344224999348323,7.758621153708097,6.906576434257317,-47.54818151025998,63.647814199681704,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-18,2.6500000953674316,2.799999952316284,2.6449999809265137,2.759999990463257,793522,0.0,0.0,2.500999999046326,2.2875000119209288,4.2808916687965395,10.355857317700604,9.333332721870038,-46.56487038449166,68.09973330753334,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-19,2.799999952316284,2.9200000762939453,2.5899999141693115,2.7200000286102295,912109,0.0,0.0,2.5589999914169312,2.2952500104904177,4.21589166522026,6.29152159958202,11.491122087835612,-45.55718712068704,65.53864407732127,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-20,2.7300000190734863,2.7799999713897705,2.5999999046325684,2.6649999618530273,513050,0.0,0.0,2.6169999837875366,2.3003750085830688,4.146099998553594,1.8341604265515212,13.764059078328064,-44.51713635981823,62.08140691903778,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-21,2.6700000762939453,2.765000104904175,2.549999952316284,2.615000009536743,405609,0.0,0.0,2.6429999828338624,2.3063750088214876,4.07689166466395,-1.0594011910320655,14.595413700063615,-43.42810163900695,59.03270168384505,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-22,2.6449999809265137,2.7249999046325684,2.549999952316284,2.7100000381469727,542708,0.0,0.0,2.643499994277954,2.316625010967255,4.012974997361501,2.515605977414896,14.109965219369702,-42.27163108440951,62.77334837403759,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-25,2.744999885559082,2.8450000286102295,2.569999933242798,2.744999885559082,599652,0.0,0.0,2.6529999732971192,2.329750007390976,3.9518499970436096,3.4677690609859417,13.874877771462787,-41.04659819745515,64.07482206144243,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-26,2.7750000953674316,2.9749999046325684,2.7750000953674316,2.934999942779541,875810,0.0,0.0,2.6914999723434447,2.345750004053116,3.8923083305358888,9.0469988087752,14.739420982326468,-39.733705430007504,70.17140491099703,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-27,2.950000047683716,3.049999952316284,2.944999933242798,3.009999990463257,883008,0.0,0.0,2.7334999799728394,2.3647500038146974,3.8388083279132843,10.11523733368254,15.593613513618475,-38.39885188797279,72.17846825877665,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-28,3.005000114440918,3.0250000953674316,2.8550000190734863,2.8949999809265137,692636,0.0,0.0,2.7679999828338624,2.380750000476837,3.784349991877874,4.588150248564287,16.2658818556952,-37.08959251690515,64.96074392152943,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-11-29,2.8949999809265137,2.930000066757202,2.7850000858306885,2.9000000953674316,477398,0.0,0.0,2.7954999923706056,2.3977500021457674,3.73018332918485,3.7381542937587025,16.58846793322441,-35.72031746038221,65.12404366651297,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-02,2.9000000953674316,2.9600000381469727,2.815000057220459,2.9000000953674316,624753,0.0,0.0,2.809500002861023,2.414750003814697,3.677433333794276,3.2212170284480877,16.34744791066239,-34.335995118551246,65.12404366651299,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-03,2.944999933242798,2.990000009536743,2.815000057220459,2.859999895095825,419338,0.0,0.0,2.8234999895095827,2.43125,3.6262666662534078,1.2927184601329575,16.133675661062533,-32.95446188153827,62.424816168279996,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-04,2.880000114440918,2.984999895095825,2.700000047683716,2.9700000286102295,1146639,0.0,0.0,2.8539999961853026,2.4511250019073487,3.578266670306524,4.064472059564617,16.43633001027919,-31.49965534297703,66.53283803121103,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-05,2.944999933242798,3.244999885559082,2.859999895095825,3.1700000762939453,1263549,0.0,0.0,2.909500002861023,2.4741250038146974,3.5318500061829883,8.953430939225388,17.597130232912576,-29.94818580960681,72.43388158397022,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-06,3.25,3.25,2.9600000381469727,2.9700000286102295,995310,0.0,0.0,2.9355000019073487,2.492625004053116,3.4776833375295,1.175269176646714,17.76741375594399,-28.32513020510247,60.87460234732496,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-09,3.009999990463257,3.25,3.009999990463257,3.200000047683716,1130012,0.0,0.0,2.981000018119812,2.517125004529953,3.425183337926865,7.346528957823763,18.428763480361322,-26.511232941665703,67.33121130548261,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-10,3.234999895095825,3.450000047683716,3.125,3.1549999713897705,2579110,0.0,0.0,3.003000020980835,2.5413750052452087,3.3736416697502136,5.061603374857439,18.164380100648927,-24.66968178533989,65.06871433176289,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-11,3.200000047683716,3.3299999237060547,3.109999895095825,3.3299999237060547,808735,0.0,0.0,3.0350000143051146,2.57012500166893,3.325558332602183,9.719931071185925,18.08764213158172,-22.715984967917905,69.37808011440437,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-12,3.3299999237060547,3.484999895095825,3.299999952316284,3.4549999237060547,1205675,0.0,0.0,3.0910000085830687,2.6023750007152557,3.281850000222524,11.776121453000112,18.77611826633424,-20.70402362878245,72.03216273691277,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-13,3.4549999237060547,3.640000104904175,3.369999885559082,3.390000104904175,2283158,0.0,0.0,3.140000009536743,2.632000005245209,3.2414333363374075,7.961786452488427,19.30091197869153,-18.801353224213322,68.69780860867738,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-16,3.450000047683716,3.5299999713897705,3.2200000286102295,3.2249999046325684,1047740,0.0,0.0,3.172499990463257,2.6575000047683717,3.1983083387215934,1.6548436352129117,19.37911513718973,-16.909199385366016,60.98101435828901,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-17,3.240000009536743,3.325000047683716,3.140000104904175,3.174999952316284,871961,0.0,0.0,3.2039999961853027,2.683125001192093,3.1522666732470195,-0.905119972020791,19.41299770833594,-14.882677155346219,58.82464498820855,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-18,3.200000047683716,3.2049999237060547,2.990000009536743,3.0999999046325684,1391438,0.0,0.0,3.2169999837875367,2.7068749964237213,3.104766670862834,-3.63693129451677,18.845531767731575,-12.81550971843356,55.646020296389025,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-19,3.055000066757202,3.059999942779541,2.930000066757202,3.009999990463257,832746,0.0,0.0,3.2009999752044678,2.7299999952316285,3.0531833390394847,-5.966884917861037,17.25274654928624,-10.585127321883263,52.01386582720032,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-20,2.9700000286102295,3.180000066757202,2.950000047683716,3.0,1185341,0.0,0.0,3.203999972343445,2.752999997138977,3.001266676187515,-6.367040390273063,16.382127703347773,-8.272063293086275,51.61076593827773,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-23,3.0399999618530273,3.0799999237060547,2.9149999618530273,3.059999942779541,875290,0.0,0.0,3.1899999618530273,2.7754999935626983,2.9481000125408174,-4.075235756365684,14.93424497393952,-5.854618847525596,53.91834984601823,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-27,3.0899999141693115,3.1050000190734863,2.9600000381469727,3.0299999713897705,508747,0.0,0.0,3.1774999618530275,2.7967499911785128,2.896266678969065,-4.642013917672535,13.614015263268916,-3.4360333084374575,52.56848919633678,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2024-12-30,3.005000114440918,3.0399999618530273,2.799999952316284,2.9200000762939453,1825905,0.0,0.0,3.1364999771118165,2.8149999916553496,2.8431000113487244,-6.902595325928579,11.420958664636089,-0.988358467208633,47.8392347314792,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-02,2.944999933242798,3.075000047683716,2.9049999713897705,3.065000057220459,612505,0.0,0.0,3.0974999904632567,2.8368749916553497,2.819558346271515,-1.0492311006573118,9.187045589761052,0.6141616259416605,53.7463271868274,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-03,3.059999942779541,3.059999942779541,2.9549999237060547,2.9600000381469727,517699,0.0,0.0,3.0544999837875366,2.856499993801117,2.797225014368693,-3.0937942754016774,6.931559265398181,2.1190636837559413,49.384886321284384,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-07,2.994999885559082,3.0,2.8299999237060547,2.8499999046325684,1654956,0.0,0.0,3.0169999837875365,2.8749999940395354,2.7759750127792358,-5.535302620231259,4.939130088431172,3.5672144311255303,45.242799615310844,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-08,2.819999933242798,2.940000057220459,2.75,2.819999933242798,1217861,0.0,0.0,2.981499981880188,2.891999989748001,2.7557250122229258,-5.416738206234885,3.0947438606314033,4.945158784734771,44.15507717809362,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-09,2.8399999141693115,2.865000009536743,2.700000047683716,2.7100000381469727,1282393,0.0,0.0,2.9424999952316284,2.907624989748001,2.7376416782538096,-7.90144290438151,1.1994327193703846,6.209114685988216,40.326678298058845,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-10,2.7300000190734863,3.0399999618530273,2.6700000762939453,2.984999895095825,1538767,0.0,0.0,2.939999985694885,2.9233749866485597,2.7247250119845075,1.5306091707447456,0.568691978355633,7.290643048025197,51.62011757772513,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-13,2.984999895095825,2.994999885559082,2.8450000286102295,2.9149999618530273,1011307,0.0,0.0,2.931499981880188,2.928624987602234,2.710225009918213,-0.5628524690141008,0.09816874096631503,8.05837068452895,49.07417359464843,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-14,2.9149999618530273,2.9700000286102295,2.805000066757202,2.8299999237060547,593029,0.0,0.0,2.9084999799728393,2.9331249833106994,2.696558344364166,-2.698987684624899,-0.8395483819467244,8.772910085218811,46.100832066627305,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-15,2.8299999237060547,3.194999933242798,2.805000066757202,3.134999990463257,1146172,0.0,0.0,2.918999981880188,2.947749984264374,2.6845166782538095,7.399794790130098,-0.9753202455316271,9.805612613358363,56.32618733104001,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-16,3.134999990463257,3.25,3.0799999237060547,3.190000057220459,494213,0.0,0.0,2.9459999799728394,2.9627499878406525,2.6689333458741507,8.282419514811714,-0.5653534026345928,11.00876657038689,57.87804825220995,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-17,3.190000057220459,3.2200000286102295,3.0999999046325684,3.174999952316284,389980,0.0,0.0,2.956999969482422,2.9783749878406525,2.6542666792869567,7.372336323426467,-0.7176738471648088,12.210841927939372,57.28025311021878,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-20,3.190000057220459,3.309999942779541,3.115000009536743,3.1549999713897705,837544,0.0,0.0,2.9764999628067015,2.991624987125397,2.641850012540817,5.996976677760539,-0.505578887186282,13.2397741326799,56.443167549859915,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-21,3.0799999237060547,3.244999885559082,3.0799999237060547,3.1549999713897705,682113,0.0,0.0,3.006999969482422,3.0014999866485597,2.6304750124613445,4.921849132337139,0.18324114137356481,14.104865943586583,56.443167549859915,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-22,3.140000104904175,3.1700000762939453,3.015000104904175,3.0799999237060547,915819,0.0,0.0,3.0329999685287476,3.010499984025955,2.6187666773796083,1.5496193757003516,0.7473836446497208,14.958694488900527,53.07016488865166,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-23,3.0799999237060547,3.0999999046325684,3.0199999809265137,3.0799999237060547,414045,0.0,0.0,3.0699999570846557,3.020874983072281,2.6074333429336547,0.32573181632534026,1.626183615265461,15.85626881926186,53.070164888651675,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-24,3.0850000381469727,3.1500000953674316,3.0299999713897705,3.055000066757202,621096,0.0,0.0,3.0769999742507936,3.0318749845027924,2.5965166787306466,-0.7149791250468942,1.4883525863914036,16.767013643254487,51.87181915059153,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-27,3.065000057220459,3.130000114440918,2.8499999046325684,2.8949999809265137,1798442,0.0,0.0,3.074999976158142,3.036499983072281,2.5856833438078564,-5.853658426902412,1.2679069092866346,17.43510628801595,44.88610243345262,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-28,2.9000000953674316,2.934999942779541,2.7899999618530273,2.805000066757202,846690,0.0,0.0,3.072499990463257,3.037999987602234,2.575933345158895,-8.706262800206627,1.1356156353460802,17.937833807374265,41.50047531212363,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-29,2.805000066757202,2.9000000953674316,2.755000114440918,2.7799999713897705,513998,0.0,0.0,3.036999988555908,3.0341249883174894,2.5760114868481954,-8.462298917832427,0.09475549786143947,17.78382991722625,40.584731156274856,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-30,2.799999952316284,2.930000066757202,2.694999933242798,2.859999895095825,1212402,0.0,0.0,3.0039999723434447,3.030374985933304,2.5766121685504912,-4.793611137595448,-0.8703547815794889,17.610831110763687,44.78350525117056,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-01-31,2.8949999809265137,2.9649999141693115,2.859999895095825,2.9149999618530273,722420,0.0,0.0,2.977999973297119,3.0308749854564665,2.5789971172809603,-2.1155141708863283,-1.7445461265497977,17.521456892977127,47.52888882564979,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-03,2.880000114440918,2.890000104904175,2.805000066757202,2.890000104904175,402917,0.0,0.0,2.9514999866485594,3.0306249856948853,2.5834797104199727,-2.083682264021216,-2.610847578298556,17.307868665329064,46.399593923201884,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-04,2.859999895095825,2.940000057220459,2.819999933242798,2.8350000381469727,677126,0.0,0.0,2.91949999332428,3.028999984264374,2.587446320056915,-2.8943296924310493,-3.6150541930982305,17.06522994447073,43.926790701479895,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-05,2.9000000953674316,2.9000000953674316,2.75,2.825000047683716,745345,0.0,0.0,2.894000005722046,3.028124988079071,2.5920213878154756,-2.3842418072530354,-4.429308000331546,16.82484574832688,43.473144286337636,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-06,2.825000047683716,2.890000104904175,2.805000066757202,2.859999895095825,399487,0.0,0.0,2.872000002861023,3.025374984741211,2.5972916622956594,-0.417831049904019,-5.069618895302256,16.481911856875676,45.5910639873761,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-07,2.940000057220459,3.0350000858306885,2.7799999713897705,3.0199999809265137,856736,0.0,0.0,2.868499994277954,3.021624982357025,2.6012083292007446,5.281505558681183,-5.0676370818070735,16.162359947750094,54.06420849965784,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-10,3.009999990463257,3.2799999713897705,3.005000114440918,3.0350000858306885,1763167,0.0,0.0,2.8825000047683718,3.0232499837875366,2.605958330631256,5.290549204164567,-4.655585207109896,16.012982565810933,54.77527316300274,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-11,3.0950000286102295,3.130000114440918,3.0199999809265137,3.119999885559082,534231,0.0,0.0,2.9139999866485597,3.0212499797344208,2.610374997059504,7.0693170849134495,-3.5498549873482736,15.740075013657156,58.6786516708799,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-12,3.119999885559082,3.119999885559082,2.994999885559082,3.0399999618530273,667245,0.0,0.0,2.939999985694885,3.018374979496002,2.6163333296775817,3.4013597498200916,-2.596595662683498,15.3666065886171,53.95825031482877,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-13,3.055000066757202,3.1600000858306885,3.009999990463257,3.075000047683716,757102,0.0,0.0,2.9615000009536745,3.0119999825954435,2.6232916633288066,3.832518882103379,-1.6766262262144227,14.817579177352641,55.63960159291207,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-14,3.069999933242798,3.2799999713897705,3.0350000858306885,3.2799999713897705,1107640,0.0,0.0,2.9980000019073487,3.0076249837875366,2.6318333288033804,9.406269823315924,-0.3200193485581121,14.278702639388566,63.944703778401,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-17,3.259999990463257,3.3550000190734863,3.194999933242798,3.299999952316284,898931,0.0,0.0,3.0389999866485597,3.0053749799728395,2.640541660785675,8.588350339400886,1.1188289947108063,13.81660909218948,64.64023947335437,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-18,3.305000066757202,3.569999933242798,3.2850000858306885,3.365000009536743,1742626,0.0,0.0,3.0919999837875367,3.0088749825954437,2.65070832769076,8.829237619037626,2.762660518397135,13.512111127545696,66.87665926967857,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-19,3.4200000762939453,3.424999952316284,3.2850000858306885,3.369999885559082,463096,0.0,0.0,3.1464999675750733,3.0137499809265136,2.6612083276112872,7.103127929038383,4.404810866485633,13.247427856640947,67.04929824952748,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-20,3.369999885559082,3.450000047683716,3.25,3.2899999618530273,260058,0.0,0.0,3.1894999742507935,3.0184999823570253,2.669874993960063,3.15096373768873,5.665065194409612,13.057727016644638,61.52389975110486,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-21,3.2300000190734863,3.2899999618530273,3.2049999237060547,3.2799999713897705,392396,0.0,0.0,3.2154999732971192,3.025249981880188,2.6790833274523416,2.005908836208575,6.288736222012677,12.921085763951638,60.84887973356746,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-24,3.2750000953674316,3.309999942779541,3.1700000762939453,3.200000047683716,387350,0.0,0.0,3.231999969482422,3.030249983072281,2.687416660785675,-0.9900965996553108,6.6578661013832505,12.756984329567175,55.59386061590568,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-25,3.1700000762939453,3.380000114440918,3.1700000762939453,3.3499999046325684,294990,0.0,0.0,3.2549999713897706,3.0374999821186064,2.696624994277954,2.918584764295286,7.160493516100748,12.640800577164594,62.1877310212915,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-26,3.3450000286102295,3.5450000762939453,3.2750000953674316,3.5299999713897705,440529,0.0,0.0,3.303999972343445,3.0499999821186066,2.7077083269755047,6.8401937329929625,8.327868580786143,12.641378383817278,68.27550608029127,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-27,3.5250000953674316,3.6549999713897705,3.4049999713897705,3.515000104904175,657800,0.0,0.0,3.3479999780654905,3.0648749828338624,2.7147083282470703,4.988056389868278,9.237733898360952,12.89886839566666,67.30307203114471,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-02-28,3.4749999046325684,3.515000104904175,3.4000000953674316,3.4800000190734863,401513,0.0,0.0,3.3679999828338625,3.075249981880188,2.7206249952316286,3.3254167699070503,9.51955134309728,13.034688252519253,64.97752672464594,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-03,3.4800000190734863,3.5899999141693115,3.3350000381469727,3.390000104904175,638931,0.0,0.0,3.3769999980926513,3.085999983549118,2.729583328962326,0.38496022561048443,9.429682958353839,13.057548044238917,59.303064342396375,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-04,3.319999933242798,3.3550000190734863,3.075000047683716,3.1500000953674316,1145746,0.0,0.0,3.35550000667572,3.0934999883174896,2.736999996503194,-6.124270925330035,8.469371887753862,13.025209801598898,47.41237347384569,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-05,3.1600000858306885,3.25,3.130000114440918,3.1700000762939453,651910,0.0,0.0,3.3355000257492065,3.1022499918937685,2.7453333298365274,-4.9617732926890685,7.5187375119646775,13.00084977580824,48.341920184438514,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-06,3.190000057220459,3.2200000286102295,2.8949999809265137,2.9600000381469727,1342435,0.0,0.0,3.302500033378601,3.108499991893768,2.7519583304723105,-10.37093086358688,6.240953578598649,12.955925148774524,40.28907390980113,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-07,2.9049999713897705,3.015000104904175,2.880000114440918,2.990000009536743,522412,0.0,0.0,3.2735000371932985,3.1086249947547913,2.759416663646698,-8.660455916769394,5.303793243530573,12.655150478311535,41.781097454444094,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-10,2.994999885559082,3.059999942779541,2.859999895095825,2.950000047683716,767737,0.0,0.0,3.248500037193298,3.1094999969005586,2.7669583300749463,-9.188855967121556,4.470173353635311,12.379719025849374,40.333939512968676,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-11,2.9749999046325684,2.9749999046325684,2.815000057220459,2.875,514178,0.0,0.0,3.2010000467300417,3.110624998807907,2.772374997536341,-10.184318711993292,2.905366219225051,12.200730477375906,37.697400861855336,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-12,2.8499999046325684,3.119999885559082,2.8499999046325684,2.940000057220459,428395,0.0,0.0,3.1420000553131104,3.1057500004768372,2.777374998728434,-6.429025924142497,1.1671916551785428,11.823214434447744,41.279908353561645,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-13,2.9649999141693115,3.0850000381469727,2.9600000381469727,3.0199999809265137,568867,0.0,0.0,3.0925000429153444,3.1014999985694884,2.7798333326975504,-2.344383540266143,-0.2901807402319874,11.571437110576435,45.43833526046069,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-14,3.0350000858306885,3.1449999809265137,3.0,3.1449999809265137,406582,0.0,0.0,3.059000039100647,3.1007499992847443,2.7848749995231628,2.8113743290814397,-1.3464471561308688,11.342519855134139,51.24786656974356,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-17,3.1449999809265137,3.190000057220459,3.119999885559082,3.140000104904175,261604,0.0,0.0,3.034000039100647,3.1003750026226045,2.7902083337306975,3.4937397639239616,-2.140868877661927,11.116254838117879,51.01388814353584,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-18,3.115000009536743,3.125,3.0399999618530273,3.065000057220459,315639,0.0,0.0,3.02550003528595,3.0981250047683715,2.7957083344459535,1.3055700371451464,-2.3441587854151624,10.817175260964774,47.50983612647517,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-19,3.3350000381469727,3.4000000953674316,3.009999990463257,3.1500000953674316,1708685,0.0,0.0,3.0235000371932985,3.099875009059906,2.801875001192093,4.183894712022645,-2.463808109791165,10.635735275164853,51.569959372218584,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-20,3.115000009536743,3.25,3.0799999237060547,3.2200000286102295,1366766,0.0,0.0,3.049500036239624,3.1033750116825103,2.808208334445953,5.591080188372494,-1.736012413584456,10.510853971053118,54.678983677101364,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-21,3.244999885559082,3.244999885559082,3.0399999618530273,3.069999933242798,597343,0.0,0.0,3.0575000286102294,3.10375000834465,2.81400000055631,0.4088276211153533,-1.490132246800624,10.29673090728707,47.62374910032152,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-24,3.059999942779541,3.065000057220459,2.8949999809265137,2.934999942779541,810584,0.0,0.0,3.056000018119812,3.104750007390976,2.8192916671435038,-3.9594265256161734,-1.5701743829652246,10.125179440433616,42.32996939347005,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-25,2.9200000762939453,2.9700000286102295,2.890000104904175,2.9200000762939453,469179,0.0,0.0,3.0605000257492065,3.1076250076293945,2.8251250008742015,-4.590751454768148,-1.5164307715536303,9.999557777718747,41.774333678210525,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-26,2.944999933242798,2.944999933242798,2.8550000190734863,2.9000000953674316,248532,0.0,0.0,3.056500029563904,3.1106250107288362,2.830166667699814,-5.120233361123228,-1.7400034069760941,9.909605191448382,41.001530081776444,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-27,2.8949999809265137,2.930000066757202,2.8450000286102295,2.880000114440918,301510,0.0,0.0,3.042500042915344,3.1111250162124633,2.835416668653488,-5.34100003886007,-2.205792854337443,9.723733044494884,40.200632155980685,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-28,2.880000114440918,2.924999952316284,2.819999933242798,2.9149999618530273,549855,0.0,0.0,3.0195000410079955,3.1111250162124633,2.8409166673819226,-3.4608404615249833,-2.9450753257101057,9.511308512951002,42.323850306843596,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-03-31,2.9000000953674316,2.9000000953674316,2.809999942779541,2.825000047683716,263918,0.0,0.0,2.9880000352859497,3.109500014781952,2.845958334207535,-5.4551534697902,-3.907379929841296,9.260208675816779,38.53494782027057,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-01,2.819999933242798,2.865000009536743,2.755000114440918,2.7899999618530273,666255,0.0,0.0,2.9605000257492065,3.1083750128746033,2.850708333651225,-5.759164411864211,-4.757308449363807,9.038689654137837,37.1424006153745,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-02,2.765000104904175,2.809999942779541,2.7049999237060547,2.7899999618530273,373679,0.0,0.0,2.924500012397766,3.107500010728836,2.8556249996026355,-4.599078474082944,-5.88897820432023,8.820311180958608,37.1424006153745,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-03,2.734999895095825,2.7899999618530273,2.640000104904175,2.6700000762939453,1615247,0.0,0.0,2.869500017166138,3.1027500152587892,2.859750000635783,-6.9524286349095314,-7.517524677965295,8.497246772234712,32.47584261555332,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-04,2.700000047683716,2.75,2.450000047683716,2.549999952316284,1676013,0.0,0.0,2.8175000190734862,3.0910000145435332,2.8622500002384186,-9.494234780703477,-8.848268980368685,7.991964862819821,28.605402853864973,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-07,2.375,2.569999933242798,2.305000066757202,2.4549999237060547,1548775,0.0,0.0,2.7695000171661377,3.0765000104904177,2.86412499944369,-11.355843708637778,-9.97887184389581,7.415004969684569,25.96695985655701,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-08,2.450000047683716,2.700000047683716,2.450000047683716,2.674999952316284,983782,0.0,0.0,2.7450000047683716,3.0653750121593477,2.867916665474574,-2.5500929810742985,-10.451413158917015,6.885079648996674,39.81197473114908,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-09,2.5250000953674316,2.619999885559082,2.490000009536743,2.509999990463257,831205,0.0,0.0,2.705999994277954,3.0521250128746034,2.8706249992052713,-7.243163497012355,-11.34046007737593,6.322665402815768,34.587602715185554,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-10,2.7300000190734863,2.744999885559082,2.625,2.694999933242798,882041,0.0,0.0,2.687499976158142,3.0426250100135803,2.874916664759318,0.2790681730675613,-11.671666166112699,5.833502838883243,43.53456286621825,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-11,2.7149999141693115,2.7950000762939453,2.6549999713897705,2.740000009536743,1387900,0.0,0.0,2.6699999809265136,3.0291250109672547,2.879708331823349,2.621723936714747,-11.855734865365163,5.188604605984494,45.48771539516303,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-14,2.744999885559082,2.9700000286102295,2.744999885559082,2.924999952316284,1230777,0.0,0.0,2.6799999713897704,3.019750010967255,2.8857083320617676,9.141790430671678,-11.250932638250383,4.645018258297704,52.72720246811326,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-15,2.944999933242798,3.069999933242798,2.875,3.009999990463257,678942,0.0,0.0,2.7019999742507936,3.0108750104904174,2.892416665951411,11.398964439215622,-10.258646910398102,4.095479947044275,55.642057855942426,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-16,3.0399999618530273,3.109999895095825,2.9649999141693115,3.049999952316284,471567,0.0,0.0,2.727999973297119,3.0028750121593477,2.899916664759318,11.803518408029499,-9.153728934744038,3.5503898664127607,56.98618038011414,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-17,3.0350000858306885,3.125,3.0,3.0899999141693115,436569,0.0,0.0,2.769999957084656,2.9978750109672547,2.907749996582667,11.552345200086078,-7.601219298634993,3.0994760378473796,58.345477244665794,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-22,3.049999952316284,3.174999952316284,3.0399999618530273,3.174999952316284,546728,0.0,0.0,2.832499957084656,2.9952500104904174,2.9168333292007445,12.091791718300525,-5.433604969059467,2.688418309837411,61.154717099078944,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-23,3.200000047683716,3.200000047683716,3.0999999046325684,3.140000104904175,280366,0.0,0.0,2.900999975204468,2.993750011920929,2.9256666640440625,8.238542976301186,-3.09812229969557,2.327105432536082,59.37893062481482,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-24,3.1449999809265137,3.1449999809265137,3.009999990463257,3.0299999713897705,336186,0.0,0.0,2.9364999771118163,2.985750013589859,2.932916663090388,3.184062489587205,-1.6495030144478764,1.8013928307052844,54.065302419220394,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-25,3.0899999141693115,3.184999942779541,3.065000057220459,3.1700000762939453,495032,0.0,0.0,3.002499985694885,2.9767500162124634,2.9411666631698608,5.578687473675201,0.8650363430646846,1.2098380376803417,59.08380203220024,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-28,3.1700000762939453,3.2300000190734863,3.0999999046325684,3.1500000953674316,272229,0.0,0.0,3.0480000019073485,2.9676250159740447,2.9491666634877522,3.346459757094962,2.708394271535781,0.625883667912589,58.10713085976287,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-29,3.0999999046325684,3.115000009536743,3.0399999618530273,3.059999942779541,262118,0.0,0.0,3.0799999952316286,2.9571250140666963,2.9564166625340778,-0.6493523533458153,4.155217671908712,0.023959800443396934,53.7974972035662,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-04-30,3.0450000762939453,3.2799999713897705,3.0,3.259999990463257,1470059,0.0,0.0,3.1134999990463257,2.9538750112056733,2.965458329518636,4.70531528703403,5.4039181493836725,-0.39060802836648867,60.76198917059699,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-02,3.5,3.640000104904175,3.380000114440918,3.5999999046325684,2438703,0.0,0.0,3.172499990463257,2.965125006437302,2.9778749962647755,13.47517464001274,6.9938024054885695,-0.42815732169638754,69.24841525454187,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-05,3.615000009536743,3.865000009536743,3.5450000762939453,3.7799999713897705,1687233,0.0,0.0,3.2454999923706054,2.9803750038146974,2.991541661818822,16.468956409664052,8.895692260757931,-0.37327436039568823,72.62412018404783,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-06,3.7899999618530273,3.8499999046325684,3.6500000953674316,3.7300000190734863,830384,0.0,0.0,3.309500002861023,2.99962500333786,3.0052499949932097,12.70584728354574,10.330457946521529,-0.1871721708583573,70.31510281465152,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-07,3.7300000190734863,3.765000104904175,3.5850000381469727,3.6549999713897705,949880,0.0,0.0,3.3575000047683714,3.0162500023841856,3.016083327929179,8.86075848693627,11.31371743437864,0.00552618866538607,66.88015442829644,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-08,3.6649999618530273,3.865000009536743,3.6549999713897705,3.7950000762939453,743352,0.0,0.0,3.4230000019073485,3.0373750030994415,3.025166662534078,10.867662114499344,12.695995667785573,0.4035592721736917,69.84177166854266,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-09,3.8499999046325684,3.9549999237060547,3.7950000762939453,3.8550000190734863,749193,0.0,0.0,3.50550000667572,3.0618750035762785,3.035208328564962,9.970047403571353,14.488671241683162,0.8785780784913907,71.03710691603958,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-12,3.8350000381469727,3.9149999618530273,3.7300000190734863,3.9000000953674316,793195,0.0,0.0,3.578500008583069,3.085875004529953,3.0464583297570544,8.98421366531344,15.963867730545154,1.293852418327413,71.93554391367809,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-13,3.859999895095825,3.934999942779541,3.825000047683716,3.884999990463257,530062,0.0,0.0,3.651999998092651,3.1075000047683714,3.0572499970595044,6.380065511837232,17.52212365209203,1.6436342385214817,71.14332433515375,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-14,3.8499999046325684,3.9749999046325684,3.7750000953674316,3.825000047683716,756642,0.0,0.0,3.728500008583069,3.1245000064373016,3.067874997854233,2.5881732299450793,19.331093003724323,1.8457404106319242,67.92115524838017,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-15,3.8299999237060547,3.890000104904175,3.700000047683716,3.815000057220459,1247626,0.0,0.0,3.784000015258789,3.1413750052452087,3.077791664997737,0.8192400062543268,20.456806619412777,2.065875379759295,67.37346314836546,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-16,3.815000057220459,3.815000057220459,3.549999952316284,3.734999895095825,1112703,0.0,0.0,3.7975000143051147,3.1581250011920927,3.085916664203008,-1.6458227511218622,20.245399180579557,2.339931529153396,62.99696259563401,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-19,3.734999895095825,3.944999933242798,3.734999895095825,3.869999885559082,866295,0.0,0.0,3.8065000057220457,3.1761249959468842,3.0954999963442487,1.6681959737706915,19.84729853452227,2.6045872943903348,66.90394857551803,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-20,3.9000000953674316,4.230000019073486,3.869999885559082,4.135000228881836,2086349,0.0,0.0,3.8470000267028808,3.1990000009536743,3.1077499985694885,7.486358205871636,20.25633090203273,2.9362079454971792,72.94314521827752,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-21,4.190000057220459,4.28000020980835,4.139999866485596,4.255000114440918,787631,0.0,0.0,3.9070000410079957,3.2286250054836274,3.1214166661103566,8.907091624783787,21.011267470585423,3.434605207861105,75.15408569165453,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-22,4.275000095367432,4.275000095367432,4.114999771118164,4.21999979019165,684367,0.0,0.0,3.949500012397766,3.26075000166893,3.1339999973773955,6.848962576142957,21.12244147439445,4.044352405794575,73.27337558795398,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-23,4.264999866485596,4.315000057220459,4.0,4.090000152587891,1466587,0.0,0.0,3.9730000257492066,3.290000003576279,3.1452083329359692,2.9448810994311723,20.759879070835762,4.603563748832828,66.60624488559984,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-26,4.105000019073486,4.315000057220459,4.105000019073486,4.260000228881836,1023476,0.0,0.0,4.009000039100647,3.324000006914139,3.1562500019868214,6.260917618686207,20.607702489821378,5.31485163791591,70.39927875728242,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-27,4.295000076293945,4.385000228881836,4.235000133514404,4.369999885559082,645164,0.0,0.0,4.05750002861023,3.3612500011920927,3.167583334445953,7.701783234635966,20.71402089018094,6.1140196262591475,72.57032475758267,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-28,4.375,4.394999980926514,4.255000114440918,4.295000076293945,249353,0.0,0.0,4.104500031471252,3.3957500040531157,3.1792500019073486,4.641248467828827,20.87167861509779,6.809782244739505,68.86182079999008,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-05-30,4.289999961853027,4.289999961853027,4.130000114440918,4.130000114440918,712658,0.0,0.0,4.136000037193298,3.428375005722046,3.1895000020662945,-0.14506582926560938,20.640245897552283,7.489418513904937,61.42490992645095,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-02,4.170000076293945,4.434999942779541,4.099999904632568,4.28000020980835,2784512,0.0,0.0,4.190500068664551,3.465625011920929,3.201000003019969,2.1357866526016154,20.916142232648465,8.266948099072192,65.11352655673943,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-03,4.284999847412109,4.320000171661377,4.144999980926514,4.170000076293945,572509,0.0,0.0,4.220500087738037,3.500125014781952,3.2119166711966196,-1.196540940511075,20.58140980432844,8.973095291353197,60.541623680330886,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-04,4.269999980926514,4.75,4.264999866485596,4.664999961853027,2408106,0.0,0.0,4.273500061035156,3.550000011920929,3.2260416706403094,9.161106709403901,20.38028300520304,10.041976339887754,70.559359974045,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-05,4.690000057220459,4.900000095367432,4.545000076293945,4.855000019073486,1377539,0.0,0.0,4.333500051498413,3.607625013589859,3.240083336830139,12.034151641344772,20.120578917548137,11.343587141165816,73.35557201995746,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-09,4.909999847412109,5.0,4.800000190734863,4.840000152587891,1269480,0.0,0.0,4.3955000877380375,3.667250019311905,3.25566667119662,10.112616448122898,19.858206137872642,12.64206043439969,72.76797244306812,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-10,4.869999885559082,4.989999771118164,4.715000152587891,4.760000228881836,998792,0.0,0.0,4.462500095367432,3.719375026226044,3.268666672706604,6.666669516113677,19.979837039864677,13.788752376706345,69.56730601288206,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-11,4.804999828338623,4.840000152587891,4.619999885559082,4.630000114440918,1193331,0.0,0.0,4.49950008392334,3.7723750293254854,3.2809583405653635,2.9003228821764746,19.27499384195285,14.977839940370675,64.59521219155141,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-12,4.71999979019165,4.730000019073486,4.579999923706055,4.585000038146973,538293,0.0,0.0,4.521000099182129,3.8196250319480898,3.291416674852371,1.4156146330636328,18.36240629296335,16.048054964642546,62.91884531110031,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-13,4.514999866485596,4.545000076293945,4.364999771118164,4.414999961853027,1142150,0.0,0.0,4.533000087738037,3.861500030755997,3.2994166751702627,-2.6031353099728567,17.389616771557424,17.035840299156167,56.9101645128574,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-16,4.440000057220459,4.449999809265137,4.199999809265137,4.28000020980835,2665207,0.0,0.0,4.54800009727478,3.8953750371932983,3.3068333427111307,-5.892697487562052,16.753844080484544,17.797742839971715,52.6132011214016,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-17,4.230000019073486,4.375,4.210000038146973,4.260000228881836,603243,0.0,0.0,4.5460000991821286,3.926625043153763,3.315458345413208,-6.291242060283872,15.7737255078193,18.433852398902175,51.98695152619596,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-18,4.25,4.275000095367432,4.175000190734863,4.230000019073486,726866,0.0,0.0,4.552000093460083,3.956125044822693,3.3242500126361847,-7.073815197174933,15.062088328507226,19.008047823858494,51.00620863507085,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-19,4.199999809265137,4.239999771118164,4.125,4.215000152587891,776796,0.0,0.0,4.50700011253357,3.9842500507831575,3.333541681369146,-6.478809688370163,13.12041300338714,19.520030994385344,50.493297256645356,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-23,4.119999885559082,4.315000057220459,4.065000057220459,4.284999847412109,790422,0.0,0.0,4.4500000953674315,4.012000048160553,3.344166680177053,-3.7078706611060914,10.917249300824288,19.97009813961016,52.8748775020899,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
2025-06-24,4.300000190734863,4.425000190734863,4.264999866485596,4.340000152587891,795533,0.0,0.0,4.400000095367432,4.042000049352646,3.3553333481152854,-1.3636350336153933,8.857002514686302,20.464932392576326,54.71810706168046,,,0.0,0.0,-1.4095501,47.112,7.2093024,-36.166668,Ascelia Pharma AB (publ),Healthcare,"Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden."
